Vol 80, Supp. III (2022): Zeszyty Edukacyjne 3/2022
Wytyczne ESC
Published online: 2022-12-22

open access

Page views 348
Article views/downloads 3266
Get Citation

Connect on Social Media

Connect on Social Media

Wytyczne ESC 2022 dotyczące oceny ryzyka sercowo-naczyniowego i postępowania u pacjentów poddawanych operacjom niekardiochirurgicznym

Sigrun Halvorsen, Julinda Mehilli, Salvatore Cassese, Trygve S. Hall, Magdy Abdelhamid, Emanuele Barbato, Stefan De Hert, Ingrid de Laval, Tobias Geisler, Lynne Hinterbuchner, Borja Ibanez, Radosław Lenarczyk, Ulrich R. Mansmann, Paul McGreavy, Christian Mueller, Claudio Muneretto, Alexander Niessner, Tatjana S. Potpara, Arsen Ristić, L. Elif Sade, Henrik Schirmer, Stefanie Schüpke, Henrik Sillesen, Helge Skulstad, Lucia Torracca, Oktay Tutarel, Peter Van Der Meer, Wojtek Wojakowski, Kai Zacharowski
DOI: 10.33963/v.kp.92024

Abstract

Not available

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008; 372(9633): 139–144.
  2. Weiser TG, Haynes AB, Molina G, et al. Estimate of the global volume of surgery in 2012: an assessment supporting improved health outcomes. Lancet. 2015; 385(Suppl. 2): S11.
  3. Eurostat. EU population in 2020: almost 448 million. https://ec.europa.eu/eurostat/documents/2995521/11081093/3-10072020-AP-EN.pdf/d2f799bf-4412-05cc-a357-7b49b93615f1 (March 31, 2022).
  4. Smilowitz NR, Gupta N, Guo Yu, et al. Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. Heart. 2018; 104(14): 1180–1186.
  5. Lee OH, Hong SJ, Ahn CM, et al. The incidence of non-cardiac surgery in patients treated with drug-eluting stents according to age. J Invasive Cardiol. 2019; 31(2): E9–E14.
  6. Spence J, LeManach Y, Chan MTV, et al. Vascular Events in Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Association between complications and death within 30 days after noncardiac surgery. CMAJ. 2019; 191(30): E830–E837.
  7. Pearse RM, Moreno RP, Bauer P, et al. Mortality after surgery in Europe: a 7 day cohort study. Lancet. 2012; 380(9847): 1059–1065.
  8. Sazgary L, Puelacher C, Buse GL, et al. Incidence of major adverse cardiac events following non-cardiac surgery. Eur Heart J Acute Cardiovasc Care. 2020; 10(5): 550–558.
  9. Smilowitz NR, Berger JS. Perioperative cardiovascular risk assessment and management for noncardiac surgery: a review. JAMA. 2020; 324(3): 279–290.
  10. Kristensen SD, Knuuti J, Saraste A, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014; 35(35): 2383–2431.
  11. Kamel H, Johnston SC, Kirkham JC, et al. Association between major perioperative hemorrhage and stroke or Q-wave myocardial infarction. Circulation. 2012; 126(2): 207–212.
  12. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734): 23–32.
  13. Kougias P, Sharath S, Barshes NR, et al. Effect of postoperative anemia and baseline cardiac risk on serious adverse outcomes after major vascular interventions. J Vasc Surg. 2017; 66(6): 1836–1843.
  14. Cohn SL. The cardiac consult for patients undergoing non-cardiac surgery. Heart. 2016; 102(16): 1322–1332.
  15. Guay J, Choi P, Suresh S, et al. Neuraxial blockade for the prevention of postoperative mortality and major morbidity: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2014(1): CD010108.
  16. Norderud K, Egholm G, Thim T, et al. Validation of the European Society of Cardiology and European Society of Anaesthesiology non-cardiac surgery risk score in patients treated with coronary drug-eluting stent implantation. Eur Heart J Qual Care Clin Outcomes. 2019; 5(1): 22–27.
  17. Mangano DT. Perioperative medicine: NHLBI working group deliberations and recommendations. J Cardiothorac Vasc Anesth. 2004; 18(1): 1–6.
  18. Glance LG, Lustik SJ, Hannan EL, et al. The Surgical Mortality Probability Model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg. 2012; 255(4): 696–702.
  19. Müller MD, Lyrer P, Brown MM, et al. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis. Cochrane Database Syst Rev. 2020; 2: CD000515.
  20. Bendixen M, Jørgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial. Lancet Oncol. 2016; 17(6): 836–844.
  21. Falcoz PE, Puyraveau M, Thomas PA, et al. ESTS Database Committee and ESTS Minimally Invasive Interest Group. Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg. 2016; 49(2): 602–609.
  22. Martin D, Mantziari S, Demartines N, et al. ESA Study Group. Defining Major Surgery: A Delphi Consensus Among European Surgical Association (ESA) Members. World J Surg. 2020; 44(7): 2211–2219.
  23. Bolliger M, Kroehnert JA, Molineus F, et al. Experiences with the standardized classification of surgical complications (Clavien-Dindo) in general surgery patients. Eur Surg. 2018; 50(6): 256–261.
  24. Björck M, Earnshaw JJ, Acosta S, et al. Editor's Choice — European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the management of acute limb ischaemia. Eur J Vasc Endovasc Surg. 2020; 59(2): 173–218.
  25. Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000; 87(11): 1480–1493.
  26. Popescu WM, Bell R, Duffy AJ, et al. A pilot study of patients with clinically severe obesity undergoing laparoscopic surgery: evidence for impaired cardiac performance. J Cardiothorac Vasc Anesth. 2011; 25(6): 943–949.
  27. Lestar M, Gunnarsson L, Lagerstrand L, et al. Hemodynamic perturbations during robot-assisted laparoscopic radical prostatectomy in 45° Trendelenburg position. Anesth Analg. 2011; 113(5): 1069–1075.
  28. Hirvonen EA, Nuutinen LS, Kauko M. Hemodynamic changes due to Trendelenburg positioning and pneumoperitoneum during laparoscopic hysterectomy. Acta Anaesthesiol Scand. 1995; 39(7): 949–955.
  29. Nguyen NT, Wolfe BM. The physiologic effects of pneumoperitoneum in the morbidly obese. Ann Surg. 2005; 241(2): 219–226.
  30. Keus F, Gooszen HG, van Laarhoven CJ. Open, small-incision, or laparoscopic cholecystectomy for patients with symptomatic cholecystolithiasis. An overview of Cochrane Hepato-Biliary Group reviews. Cochrane Database Syst Rev. 2010(1): CD008318.
  31. Mamidanna R, Burns EM, Bottle A, et al. Reduced risk of medical morbidity and mortality in patients selected for laparoscopic colorectal resection in England: a population-based study. Arch Surg. 2012; 147(3): 219–227.
  32. Cirocchi R, Farinella E, Trastulli S, et al. Elective sigmoid colectomy for diverticular disease. Laparoscopic vs open surgery: a systematic review. Colorectal Dis. 2012; 14(6): 671–683.
  33. Murr MM, Martin T, Haines K, et al. A state-wide review of contemporary outcomes of gastric bypass in Florida: does provider volume impact outcomes? Ann Surg. 2007; 245(5): 699–706.
  34. Grailey K, Markar SR, Karthikesalingam A, et al. Laparoscopic versus open colorectal resection in the elderly population. Surg Endosc. 2013; 27(1): 19–30.
  35. Wanhainen A, Verzini F, Van Herzeele I, et al. Editor's Choice — European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg. 2019; 57(1): 8–93.
  36. Powell JT, Sweeting MJ, Ulug P, et al. Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Br J Surg. 2017; 104(3): 166–178.
  37. Lederle FA, Kyriakides TC, Stroupe KT, et al. Open versus endovascular repair of abdominal aortic aneurysm. N Engl J Med. 2019; 380(22): 2126–2135.
  38. Bauer SM, Cayne NS, Veith FJ. New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery. J Vasc Surg. 2010; 51(1): 242–251.
  39. Antoniou GA, Chalmers N, Georgiadis GS, et al. A meta-analysis of endovascular versus surgical reconstruction of femoropopliteal arterial disease. J Vasc Surg. 2013; 57(1): 242–253.
  40. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  41. Botto F, Alonso-Coello P, Chan MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology. 2014; 120(3): 564–578.
  42. Noordzij PG, Boersma E, Bax JJ, et al. Prognostic value of routine preoperative electrocardiography in patients undergoing noncardiac surgery. Am J Cardiol. 2006; 97(7): 1103–1106.
  43. Chivulescu M, Lie ØH, Popescu BA, et al. High penetrance and similar disease progression in probands and in family members with arrhythmogenic cardiomyopathy. Eur Heart J. 2020; 41(14): 1401–1410.
  44. Hallqvist L, Granath F, Bell M. Myocardial infarction after noncardiac surgery in Sweden: a national, retrospective observational cohort study. Br J Anaesth. 2020; 125(1): 47–54.
  45. Chaudhry W, Cohen MC. Cardiac screening in the noncardiac surgery patient. Surg Clin North Am. 2017; 97(4): 717–732.
  46. Ford MK, Beattie WS, Wijeysundera DN. Systematic review: prediction of perioperative cardiac complications and mortality by the revised cardiac risk index. Ann Intern Med. 2010; 152(1): 26–35.
  47. Duceppe E, Parlow J, MacDonald P, et al. Canadian Cardiovascular Society guidelines on perioperative cardiac risk assessment and management for patients who undergo noncardiac surgery. Can J Cardiol. 2017; 33(1): 17–32.
  48. Yap MaK, Ang KF, Gonzales-Porciuncula LA, et al. Validation of the American College of Surgeons Risk Calculator for preoperative risk stratification. Heart Asia. 2018; 10(2): e010993.
  49. Dakik HA, Chehab O, Eldirani M, et al. A new index for pre-operative cardiovascular evaluation. J Am Coll Cardiol. 2019; 73(24): 3067–3078.
  50. Dakik HA, Sbaity E, Msheik A, et al. AUB-HAS2 Cardiovascular Risk Index: performance in surgical subpopulations and comparison to the Revised Cardiac Risk Index. J Am Heart Assoc. 2020; 9(10): e016228.
  51. Dakik HA, Eldirani M, Kaspar C, et al. Prospective validation of the AUB-HAS2 cardiovascular risk index. Eur Heart J Qual Care Clin Outcomes. 2022; 8(1): 96–97.
  52. Duceppe E, Patel A, Chan MTV, et al. Preoperative N-terminal pro-B-type natriuretic peptide and cardiovascular events after noncardiac surgery: a cohort study. Ann Intern Med. 2020; 172(2): 96–104.
  53. Weber M, Luchner A, Seeberger M, et al. Incremental value of high-sensitive troponin T in addition to the revised cardiac index for peri-operative risk stratification in non-cardiac surgery. Eur Heart J. 2013; 34(11): 853–862.
  54. Kueh SH, Pasley T, Wheeler M, et al. The not so innocent heart murmur: a 5-year experience. Intern Med J. 2017; 47(2): 199–205.
  55. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr. 2011; 24(3): 229–267.
  56. Friedman JM, Couso R, Kitchens M, et al. Benign heart murmurs as a predictor for complications following total joint arthroplasty. J Orthop. 2017; 14(4): 470–474.
  57. Hip Attack Investigators. Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. Lancet. 2020; 395(10225): 698–708.
  58. Cowie B. The preoperative patient with a systolic murmur. Anesth Pain Med. 2015; 5(6): e32105.
  59. Attenhofer JC, Turina J, Mayer K, et al. Echocardiography in the evaluation of systolic murmurs of unknown cause. Am J Med. 2000; 108(8): 614–620.
  60. Kobal SL, Trento L, Baharami S, et al. Comparison of effectiveness of hand-carried ultrasound to bedside cardiovascular physical examination. Am J Cardiol. 2005; 96(7): 1002–1006.
  61. Abidov A, Rozanski A, Hachamovitch R, et al. Prognostic significance of dyspnea in patients referred for cardiac stress testing. N Engl J Med. 2005; 353(18): 1889–1898.
  62. Cajita MI, Cajita TR, Han HR. Health literacy and heart failure: a systematic review. J Cardiovasc Nurs. 2016; 31(2): 121–130.
  63. Magnani JW, Mujahid MS, Aronow HD, et al. Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the American Heart Association. Circulation. 2018; 138(2): e48–e74.
  64. Shinkunas LA, Klipowicz CJ, Carlisle EM. Shared decision making in surgery: a scoping review of patient and surgeon preferences. BMC Med Inform Decis Mak. 2020; 20(1): 190.
  65. de Mik SML, Stubenrouch FE, Balm R, et al. Systematic review of shared decision-making in surgery. Br J Surg. 2018; 105(13): 1721–1730.
  66. Pham C, Lizarondo L, Karnon J, et al. Strategies for implementing shared decision making in elective surgery by health care practitioners: A systematic review. J Eval Clin Pract. 2020; 26(2): 582–601.
  67. Niburski K, Guadagno E, Abbasgholizadeh-Rahimi S, et al. Shared decision making in surgery: a meta-analysis of existing literature. Patient. 2020; 13(6): 667–681.
  68. Abate S, Chekol Y, Basu B. Global prevalence and determinants of preoperative anxiety among surgical patients: A systematic review and meta-analysis. Int J Surg Open. 2020; 25: 6–16.
  69. Takagi H, Ando T, Umemoto T, et al. ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Perioperative depression or anxiety and postoperative mortality in cardiac surgery: a systematic review and meta-analysis. Heart Vessels. 2017; 32(12): 1458–1468.
  70. Tully PJ, Baker RA. Depression, anxiety, and cardiac morbidity outcomes after coronary artery bypass surgery: a contemporary and practical review. J Geriatr Cardiol. 2012; 9(2): 197–208.
  71. Rosenberger PH, Jokl P, Ickovics J. Psychosocial factors and surgical outcomes: an evidence-based literature review. J Am Acad Orthop Surg. 2006; 14(7): 397–405.
  72. Theunissen M, Peters ML, Bruce J, et al. Preoperative anxiety and catastrophizing: a systematic review and meta-analysis of the association with chronic postsurgical pain. Clin J Pain. 2012; 28(9): 819–841.
  73. Szeverenyi C, Kekecs Z, Johnson A, et al. The use of adjunct psychosocial interventions can decrease postoperative pain and improve the quality of clinical care in orthopedic surgery: a systematic review and meta-analysis of randomized controlled trials. J Pain. 2018; 19(11): 1231–1252.
  74. Villa G, Lanini I, Amass T, et al. Effects of psychological interventions on anxiety and pain in patients undergoing major elective abdominal surgery: a systematic review. Perioper Med (Lond). 2020; 9(1): 38.
  75. Richards SH, Anderson L, Jenkinson CE, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2017; 4: CD002902.
  76. Bilimoria KY, Liu Y, Paruch JL, et al. Development and evaluation of the universal ACS NSQIP surgical risk calculator: a decision aid and informed consent tool for patients and surgeons. J Am Coll Surg. 2013; 217(5): 833–842.e1-3.
  77. Bertges DJ, Goodney PP, Zhao Y, et al. The Vascular Study Group of New England Cardiac Risk Index (VSG-CRI) predicts cardiac complications more accurately than the Revised Cardiac Risk Index in vascular surgery patients. J Vasc Surg. 2010; 52(3): 674–683.e3.
  78. Protopapa KL, Simpson JC, Smith NCE, et al. Development and validation of the Surgical Outcome Risk Tool (SORT). Br J Surg. 2014; 101(13): 1774–1783.
  79. Wong DJN, Harris S, Sahni A, et al. Developing and validating subjective and objective risk-assessment measures for predicting mortality after major surgery: An international prospective cohort study. PLoS Med. 2020; 17(10): e1003253.
  80. Gupta PK, Gupta H, Sundaram A, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. 2011; 124(4): 381–387.
  81. Msheik A, Kaspar C, Mailhac A, et al. Performance of the AUB-HAS2 Cardiovascular Risk Index in vascular surgery patients. Vasc Med. 2021; 26(5): 535–541.
  82. Glance LG, Faden E, Dutton RP, et al. Impact of the choice of risk model for identifying low-risk patients using the 2014 American College of Cardiology/American Heart Association Perioperative Guidelines. Anesthesiology. 2018; 129(5): 889–900.
  83. Robinson TN, Walston JD, Brummel NE, et al. Frailty for surgeons: review of a national institute on aging conference on frailty for specialists. J Am Coll Surg. 2015; 221(6): 1083–1092.
  84. Richter D, Guasti L, Walker D, et al. Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS). Eur J Prev Cardiol. 2022; 29(1): 216–227.
  85. Hornor MA, Ma M, Zhou L, et al. Enhancing the American College of Surgeons NSQIP Surgical Risk Calculator to predict geriatric outcomes. J Am Coll Surg. 2020; 230(1): 88–100.e1.
  86. Tjeertes EKM, van Fessem JMK, Mattace-Raso FUS, et al. Influence of frailty on outcome in older patients undergoing non-cardiac surgery - a systematic review and meta-analysis. Aging Dis. 2020; 11(5): 1276–1290.
  87. Mosquera C, Spaniolas K, Fitzgerald TL. Impact of frailty on surgical outcomes: The right patient for the right procedure. Surgery. 2016; 160(2): 272–280.
  88. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005; 173(5): 489–495.
  89. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56(3): M146–M156.
  90. Alvarez-Nebreda ML, Bentov N, Urman RD, et al. Recommendations for preoperative management of frailty from the Society for Perioperative Assessment and Quality Improvement (SPAQI). J Clin Anesth. 2018; 47: 33–42.
  91. Grigoryan KV, Javedan H, Rudolph JL. Orthogeriatric care models and outcomes in hip fracture patients: a systematic review and meta-analysis. J Orthop Trauma. 2014; 28(3): e49–e55.
  92. Borson S, Scanlan JM, Chen P, et al. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003; 51(10): 1451–1454.
  93. Biccard BM. Relationship between the inability to climb two flights of stairs and outcome after major non-cardiac surgery: implications for the pre-operative assessment of functional capacity. Anaesthesia. 2005; 60(6): 588–593.
  94. Lurati Buse GAL, Puelacher C, Gualandro DM, et al. BASEL-PMI Investigators. Association between self-reported functional capacity and major adverse cardiac events in patients at elevated risk undergoing noncardiac surgery: a prospective diagnostic cohort study. Br J Anaesth. 2021; 126(1): 102–110.
  95. Wijeysundera DN, Pearse RM, Shulman MA, et al. Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study. Lancet. 2018; 391(10140): 2631–2640.
  96. Wijeysundera DN, Beattie WS, Hillis GS, et al. Integration of the Duke Activity Status Index into preoperative risk evaluation: a multicentre prospective cohort study. Br J Anaesth. 2020; 124(3): 261–270.
  97. Jeger RV, Probst C, Arsenic R, et al. Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease. Am Heart J. 2006; 151(2): 508–513.
  98. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42(14): 1289–1367.
  99. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021; 42(5): 373–498.
  100. Ganguli I, Lupo C, Mainor AJ, et al. Prevalence and cost of care cascades after low-value preoperative electrocardiogram for cataract surgery in fee-for-service medicare beneficiaries. JAMA Intern Med. 2019; 179(9): 1211–1219.
  101. Gualandro DM, Puelacher C, LuratiBuse G, et al. Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery. Am Heart J. 2018; 203: 67–73.
  102. Humble CAS, Huang S, Jammer Ib, et al. Prognostic performance of preoperative cardiac troponin and perioperative changes in cardiac troponin for the prediction of major adverse cardiac events and mortality in noncardiac surgery: A systematic review and meta-analysis. PLoS One. 2019; 14(4): e0215094.
  103. Park SJ, Choi JH, Cho SJ, et al. Comparison of transthoracic echocardiography with N-terminal pro-brain natriuretic Peptide as a tool for risk stratification of patients undergoing major noncardiac surgery. Korean Circ J. 2011; 41(9): 505–511.
  104. Lee G, Sou SM, Twerenbold R, et al. B-type natriuretic peptide and clinical judgment in the detection of exercise-induced myocardial ischemia. Am J Med. 2014; 127(5): 427–435.
  105. Walter J, du Fay de Lavallaz J, Koechlin L, et al. Using high-sensitivity cardiac troponin for the exclusion of inducible myocardial ischemia in symptomatic patients: a cohort study. Ann Intern Med. 2020; 172(3): 175–185.
  106. Walter JE, Honegger U, Puelacher C, et al. Prospective validation of a biomarker-based rule out strategy for functionally relevant coronary artery disease. Clin Chem. 2018; 64(2): 386–395.
  107. Mueller D, Puelacher C, Honegger U, et al. Direct comparison of cardiac troponin t and i using a uniform and a sex-specific approach in the detection of functionally relevant coronary artery disease. Clin Chem. 2018; 64(11): 1596–1606.
  108. Ackland GL, Abbott TEF, Cain D, et al. Preoperative systemic inflammation and perioperative myocardial injury: prospective observational multicentre cohort study of patients undergoing non-cardiac surgery. Br J Anaesth. 2019; 122(2): 180–187.
  109. Devereaux PJ, Biccard BM, Sigamani A, et al. Writing Committee for the VISION Study Investigators. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2017; 317(16): 1642–1651.
  110. Puelacher C, Gualandro DM, Lurati Buse G, et al. Etiology of peri-operative myocardial infarction/injury after noncardiac surgery and associated outcome. J Am Coll Cardiol. 2020; 76(16): 1910–1912.
  111. Puelacher C, Lurati Buse G, Seeberger D, et al. Perioperative myocardial injury after noncardiac surgery: incidence, mortality, and characterization. Circulation. 2018; 137(12): 1221–1232.
  112. Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013; 62(15): 1365–1372.
  113. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013; 310(1): 66–74.
  114. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019; 21(6): 715–731.
  115. De Hert SG, Lurati Buse GA. Cardiac biomarkers for the prediction and detection of adverse cardiac events after noncardiac surgery: a narrative review. Anesth Analg. 2020; 131(1): 187–195.
  116. Mauermann E, Bolliger D, Seeberger E, et al. Incremental value of preoperative copeptin for predicting myocardial injury. Anesth Analg. 2016; 123(6): 1363–1371.
  117. Buse GL, Manns B, Lamy A, et al. Troponin T monitoring to detect myocardial injury after noncardiac surgery: a cost-consequence analysis. Can J Surg. 2018; 61(3): 185–194.
  118. Devereaux PJ, Chan MTV, Alonso-Coello P, et al. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012; 307(21): 2295–2304.
  119. Mantha S, Foss J, Ellis JE, et al. Intense cardiac troponin surveillance for long-term benefits is cost-effective in patients undergoing open abdominal aortic surgery: a decision analysis model. Anesth Analg. 2007; 105(5): 1346–1356.
  120. Levitan EB, Graham LA, Valle JA, et al. Pre-operative echocardiography among patients with coronary artery disease in the United States Veterans Affairs healthcare system: A retrospective cohort study. BMC Cardiovasc Disord. 2016; 16(1): 173.
  121. Chang HY, Chang WT, Liu YW. Application of transthoracic echocardiography in patients receiving intermediate- or high-risk noncardiac surgery. PLoS One. 2019; 14(4): e0215854.
  122. Wijeysundera DN, Beattie WS, Karkouti K, et al. Association of echocardiography before major elective non-cardiac surgery with postoperative survival and length of hospital stay: population based cohort study. BMJ. 2011; 342: d3695.
  123. Faris JG, Hartley K, Fuller CM, et al. Audit of cardiac pathology detection using a criteria-based perioperative echocardiography service. Anaesth Intensive Care. 2012; 40(4): 702–709.
  124. Steeds RP, Garbi M, Cardim N, et al. EACVI appropriateness criteria for the use of transthoracic echocardiography in adults: a report of literature and current practice review. Eur Heart J Cardiovasc Imaging. 2017; 18(11): 1191–1204.
  125. Kertai MD, Boersma E, Bax JJ, et al. A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery. Heart. 2003; 89(11): 1327–1334.
  126. Halm EA, Browner WS, Tubau JF, et al. Echocardiography for assessing cardiac risk in patients having noncardiac surgery. Study of Perioperative Ischemia Research Group. Ann Intern Med. 1996; 125(6): 433–441.
  127. Rohde L, Polanczyk C, Goldman L, et al. Usefulness of transthoracic echocardiography as a tool for risk stratification of patients undergoing major noncardiac surgery. Am J Cardiol. 2001; 87(5): 505–509.
  128. Galasko GIW, Barnes SC, Collinson P, et al. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? Eur Heart J. 2006; 27(2): 193–200.
  129. Cardim N, Dalen H, Voigt JU, et al. The use of handheld ultrasound devices: a position statement of the European Association of Cardiovascular Imaging (2018 update). Eur Heart J Cardiovasc Imaging. 2019; 20(3): 245–252.
  130. Canty DJ, Royse CF, Kilpatrick D, et al. The impact of focused transthoracic echocardiography in the pre-operative clinic. Anaesthesia. 2012; 67(6): 618–625.
  131. Heiberg J, El-Ansary D, Canty DJ, et al. Focused echocardiography: a systematic review of diagnostic and clinical decision-making in anaesthesia and critical care. Anaesthesia. 2016; 71(9): 1091–1100.
  132. Canty DJ, Royse CF. Audit of anaesthetist-performed echocardiography on perioperative management decisions for non-cardiac surgery. Br J Anaesth. 2009; 103(3): 352–358.
  133. Canty DJ, Heiberg J, Yang Y, et al. One-year results of the pilot multicentre randomised trial of preoperative focused cardiac ultrasound in hip fracture surgery. Anaesth Intensive Care. 2019; 47(2): 207–208.
  134. Matyal R, Hess PE, Subramaniam B, et al. Perioperative diastolic dysfunction during vascular surgery and its association with postoperative outcome. J Vasc Surg. 2009; 50(1): 70–76.
  135. Saito S, Takagi A, Kurokawa F, et al. Usefulness of tissue Doppler echocardiography to predict perioperative cardiac events in patients undergoing noncardiac surgery. Heart Vessels. 2012; 27(6): 594–602.
  136. Higashi M, Yamaura K, Ikeda M, et al. Diastolic dysfunction of the left ventricle is associated with pulmonary edema after renal transplantation. Acta Anaesthesiol Scand. 2013; 57(9): 1154–1160.
  137. Brecher O, Gulati H, Roistacher N, et al. Preoperative echocardiographic indices of diastolic dysfunction and brain natriuretic peptide in predicting postoperative atrial fibrillation after noncardiac surgery. Anesth Analg. 2017; 124(4): 1099–1104.
  138. Zhou Y, Liu L, Cheng T, et al. Grade 3 echocardiographic diastolic dysfunction is associated with increased risk of major adverse cardiovascular events after surgery: a retrospective cohort study. Anesth Analg. 2019; 129(3): 651–658.
  139. Fayad A, Ansari MT, Yang H, et al. Perioperative diastolic dysfunction in patients undergoing noncardiac surgery is an independent risk factor for cardiovascular events: a systematic review and meta-analysis. Anesthesiology. 2016; 125(1): 72–91.
  140. Willingham M, Ayoubi SAl-, Doan M, et al. Preoperative diastolic dysfunction and postoperative outcomes after noncardiac surgery. J Cardiothorac Vasc Anesth. 2020; 34(3): 679–686.
  141. Sougawa H, Ino Y, Kitabata H, et al. Impact of left ventricular ejection fraction and preoperative hemoglobin level on perioperative adverse cardiovascular events in noncardiac surgery. Heart Vessels. 2021; 36(9): 1317–1326.
  142. Hreybe H, Zahid M, Sonel A, et al. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2006; 29(2): 65–68.
  143. Kertai MD, Bountioukos M, Boersma E, et al. Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing noncardiac surgery. Am J Med. 2004; 116(1): 8–13.
  144. Marbach JA, Almufleh A, Di Santo P, et al. Comparative accuracy of focused cardiac ultrasonography and clinical examination for left ventricular dysfunction and valvular heart disease: a systematic review and meta-analysis. Ann Intern Med. 2019; 171(4): 264–272.
  145. Lurati Buse GAL, Puelacher C, Gualandro DM, et al. Adherence to the European Society of Cardiology/European Society of Anaesthesiology recommendations on preoperative cardiac testing and association with positive results and cardiac events: a cohort study. Br J Anaesth. 2021; 127(3): 376–385.
  146. Storey RF, Valgimigli M, Cuisset T, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
  147. Wolk MJ, Bailey SR, Doherty JU, et al. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014; 63(4): 380–406.
  148. Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. J Am Soc Echocardiogr. 2020; 33(1): 1–41.e8.
  149. Koh AS, Flores JLS, Keng FYJ, et al. Correlation between clinical outcomes and appropriateness grading for referral to myocardial perfusion imaging for preoperative evaluation prior to non-cardiac surgery. J Nucl Cardiol. 2012; 19(2): 277–284.
  150. Nguyen P, Plotkin J, Fishbein TM, et al. Dobutamine stress echocardiography in patients undergoing orthotopic liver transplantation: a pooled analysis of accuracy, perioperative and long term cardiovascular prognosis. Int J Cardiovasc Imaging. 2013; 29(8): 1741–1748.
  151. Shaw LJ, Eagle KA, Gersh BJ, et al. Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgery. J Am Coll Cardiol. 1996; 27(4): 787–798.
  152. Beattie WS, Abdelnaem E, Wijeysundera DN, et al. A meta-analytic comparison of preoperative stress echocardiography and nuclear scintigraphy imaging. Anesth Analg. 2006; 102(1): 8–16.
  153. Bach DS, Eagle KA. Dobutamine stress echocardiography. Stressing the indications for preoperative testing. Circulation. 1997; 95(1): 8–10.
  154. Etchells E, Meade M, Tomlinson G, et al. Semiquantitative dipyridamole myocardial stress perfusion imaging for cardiac risk assessment before noncardiac vascular surgery: a meta-analysis. J Vasc Surg. 2002; 36(3): 534–540.
  155. Ballal RS, Kapadia S, Secknus MA, et al. Prognosis of patients with vascular disease after clinical evaluation and dobutamine stress echocardiography. Am Heart J. 1999; 137(3): 469–475.
  156. Boersma E, Poldermans D, Bax JJ, et al. Predictors of cardiac events after major vascular surgery: Role of clinical characteristics, dobutamine echocardiography, and beta-blocker therapy. JAMA. 2001; 285(14): 1865–1873.
  157. Cullen MW, McCully RB, Widmer RJ, et al. Preoperative dobutamine stress echocardiography and clinical factors for assessment of cardiac risk after noncardiac surgery. J Am Soc Echocardiogr. 2020; 33(4): 423–432.
  158. Van Damme H, Piérard L, Gillain D, et al. Cardiac risk assessment before vascular surgery: a prospective study comparing clinical evaluation, dobutamine stress echocardiography, and dobutamine Tc-99m sestamibi tomoscintigraphy. Cardiovasc Surg. 1997; 5(1): 54–64.
  159. Metz LD, Beattie M, Hom R, et al. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. J Am Coll Cardiol. 2007; 49(2): 227–237.
  160. Cohen MC, Siewers AE, Dickens JD, et al. Perioperative and long-term prognostic value of dipyridamole Tc-99m sestamibi myocardial tomography in patients evaluated for elective vascular surgery. J Nucl Cardiol. 2003; 10(5): 464–472.
  161. Dowsley TF, Sheth T, Chow BJW. Complementary pre-operative risk assessment using coronary computed tomography angiography and nuclear myocardial perfusion imaging in non-cardiac surgery: A VISION-CTA sub-study. J Nucl Cardiol. 2020; 27(4): 1331–1337.
  162. Das MK, Pellikka PA, Mahoney DW, et al. Assessment of cardiac risk before nonvascular surgery: dobutamine stress echocardiography in 530 patients. J Am Coll Cardiol. 2000; 35(6): 1647–1653.
  163. Torres MR, Short L, Baglin T, et al. Usefulness of clinical risk markers and ischemic threshold to stratify risk in patients undergoing major noncardiac surgery. Am J Cardiol. 2002; 90(3): 238–242.
  164. Labib SB, Goldstein M, Kinnunen PM, et al. Cardiac events in patients with negative maximal versus negative submaximal dobutamine echocardiograms undergoing noncardiac surgery: importance of resting wall motion abnormalities. J Am Coll Cardiol. 2004; 44(1): 82–87.
  165. Lancellotti P, Pellikka PA, Budts W, et al. The clinical use of stress echocardiography in non-ischaemic heart disease: recommendations from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. Eur Heart J Cardiovasc Imaging. 2016; 17(11): 1191–1229.
  166. Nandalur KR, Dwamena BA, Choudhri AF, et al. Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2007; 50(14): 1343–1353.
  167. Vavere AL, Arbab-Zadeh A, Rochitte CE, et al. Coronary artery stenoses: accuracy of 64-detector row CT angiography in segments with mild, moderate, or severe calcification — a subanalysis of the CORE-64 trial. Radiology. 2011; 261(1): 100–108.
  168. Sheth T, Chan M, Butler C, et al. Prognostic capabilities of coronary computed tomographic angiography before non-cardiac surgery: prospective cohort study. BMJ. 2015; 350: h1907.
  169. Krievins D, Zellans E, Latkovskis G, et al. Diagnosis and management of silent coronary ischemia in patients undergoing carotid endarterectomy. J Vasc Surg. 2021; 73(2): 533–541.
  170. Krievins D, Zellans E, Latkovskis G, et al. Pre-operative diagnosis of silent coronary ischaemia may reduce post-operative death and myocardial infarction and improve survival of patients undergoing lower extremity surgical revascularisation. Eur J Vasc Endovasc Surg. 2020; 60(3): 411–420.
  171. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39(2): 119–177.
  172. Illuminati G, Ricco JB, Greco C, et al. Systematic preoperative coronary angiography and stenting improves postoperative results of carotid endarterectomy in patients with asymptomatic coronary artery disease: a randomised controlled trial. Eur J Vasc Endovasc Surg. 2010; 39(2): 139–145.
  173. Sørensen LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg. 2012; 147(4): 373–383.
  174. Gourgiotis S, Aloizos S, Aravosita P, et al. The effects of tobacco smoking on the incidence and risk of intraoperative and postoperative complications in adults. Surgeon. 2011; 9(4): 225–232.
  175. World Health Organization. WHO Tobacco and postsurgical outcomes. https://apps.who.int/iris/rest/bitstreams/1265388/retrieve.
  176. Mills E, Eyawo O, Lockhart I, et al. Smoking cessation reduces postoperative complications: a systematic review and meta-analysis. Am J Med. 2011; 124(2): 144–154.e8.
  177. Lee SM, Landry J, Jones PM, et al. Long-term quit rates after a perioperative smoking cessation randomized controlled trial. Anesth Analg. 2015; 120(3): 582–587.
  178. Wong J, Abrishami A, Riazi S, et al. A perioperative smoking cessation intervention with varenicline, counseling, and fax referral to a telephone quitline versus a brief intervention: a randomized controlled trial. Anesth Analg. 2017; 125(2): 571–579.
  179. Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev. 2017; 6: CD012020.
  180. Tew GA, Ayyash R, Durrand J, et al. Clinical guideline and recommendations on pre-operative exercise training in patients awaiting major non-cardiac surgery. Anaesthesia. 2018; 73(6): 750–768.
  181. Musallam KM, Rosendaal FR, Zaatari G, et al. Smoking and the risk of mortality and vascular and respiratory events in patients undergoing major surgery. JAMA Surg. 2013; 148(8): 755–762.
  182. Turan A, Mascha EJ, Roberman D, et al. Smoking and perioperative outcomes. Anesthesiology. 2011; 114(4): 837–846.
  183. Im C, Oh TK, Song IA. Association between use of preoperative antihypertensive medication and 90-day mortality after noncardiac surgery: a retrospective cohort study. Am J Hypertens. 2020; 33(6): 534–542.
  184. Clemente-Moragón A, Gómez M, Villena-Gutiérrez R, et al. Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. Eur Heart J. 2020; 41(46): 4425–4440.
  185. Devereaux PJ, Yang H, Yusuf S, et al. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008; 371(9627): 1839–1847.
  186. Alonso-Coello P, Paniagua P, Mizera R, et al. Should physicians initiate beta-blocker therapy in patients undergoing non-cardiac surgery? Insights from the POISE trial. Pol Arch Med Wewn. 2008; 118(11): 616–618.
  187. Blessberger H, Lewis SR, Pritchard MW, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery. Cochrane Database Syst Rev. 2019; 9: CD013438.
  188. Friedell ML, Van Way CW, Freyberg RW, et al. β-blockade and operative mortality in noncardiac surgery: harmful or helpful? JAMA Surg. 2015; 150(7): 658–663.
  189. Wijeysundera DN, Duncan D, Nkonde-Price C, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014; 64: 2406–2425.
  190. London MJ, Hur K, Schwartz GG, et al. Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA. 2013; 309(16): 1704–1713.
  191. Angeli F, Verdecchia P, Karthikeyan G, et al. ß-blockers reduce mortality in patients undergoing high-risk non-cardiac surgery. Am J Cardiovasc Drugs. 2010; 10(4): 247–259.
  192. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005; 353(4): 349–361.
  193. Wallace AW, Au S, Cason BA. Perioperative β-blockade: atenolol is associated with reduced mortality when compared to metoprolol. Anesthesiology. 2011; 114(4): 824–836.
  194. Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ. 2005; 331(7522): 932.
  195. Ashes C, Judelman S, Wijeysundera DN, et al. Selective β1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44,092 consecutive patients. Anesthesiology. 2013; 119(4): 777–787.
  196. Shammash JB, Trost JC, Gold JM, et al. Perioperative beta-blocker withdrawal and mortality in vascular surgical patients. Am Heart J. 2001; 141(1): 148–153.
  197. Wallace AW, Au S, Cason BA. Association of the pattern of use of perioperative β-blockade and postoperative mortality. Anesthesiology. 2010; 113(4): 794–805.
  198. Kwon S, Thompson R, Florence M, et al. β-blocker continuation after noncardiac surgery: a report from the surgical care and outcomes assessment program. Arch Surg. 2012; 147(5): 467–473.
  199. Kertai MD, Cooter M, Pollard RJ, et al. Is compliance with Surgical Care Improvement Project Cardiac (SCIP-Card-2) measures for perioperative β-Blockers associated with reduced incidence of mortality and cardiovascular-related critical quality indicators after noncardiac surgery? Anesth Analg. 2018; 126(6): 1829–1838.
  200. Longrois D, Couffignal C, Ait-Hamou N, et al. Indispensable optimisation de la réintroduction des bêtabloquants après chirurgie cardiaque. Résultats de l’étude Bêtabloquants Avant et Après Chirurgie Cardiaque (BBAACC). Anesthésie & Réanimation. 2015; 1: A248.
  201. Oesterle A, Weber B, Tung R, et al. Preventing postoperative atrial fibrillation after noncardiac surgery: a meta-analysis. Am J Med. 2018; 131(7): 795–804.e5.
  202. Aoki Y, Kawasaki Y, Ide K, et al. Landiolol hydrochloride for prevention of atrial fibrillation during esophagectomy: a randomized controlled trial. JA Clin Rep. 2020; 6(1): 34.
  203. Aoyama H, Otsuka Y, Aoyama Y. Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection. Gen Thorac Cardiovasc Surg. 2016; 64(12): 735–741.
  204. Ojima T, Nakamori M, Nakamura M, et al. Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. Br J Surg. 2017; 104(8): 1003–1009.
  205. Horikoshi Y, Goyagi T, Kudo R, et al. The suppressive effects of landiolol administration on the occurrence of postoperative atrial fibrillation and tachycardia, and plasma IL-6 elevation in patients undergoing esophageal surgery: A randomized controlled clinical trial. J Clin Anesth. 2017; 38: 111–116.
  206. O'Brien B, Burrage PS, Ngai JY, et al. Society of Cardiovascular Anesthesiologists/European Association of Cardiothoracic Anaesthetists Practice Advisory for the management of perioperative atrial fibrillation in patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2019; 33(1): 12–26.
  207. Zhu J, Wang C, Gao D, et al. Meta-analysis of amiodarone versus β-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. Intern Med J. 2012; 42(10): 1078–1087.
  208. Auer J, Weber T, Berent R, et al. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. Am Heart J. 2004; 147(4): 636–643.
  209. London MJ, Schwartz GG, Hur K, et al. Association of perioperative statin use with mortality and morbidity after major noncardiac surgery. JAMA Intern Med. 2017; 177(2): 231–242.
  210. Lindenauer PK, Pekow P, Wang K, et al. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA. 2004; 291(17): 2092–2099.
  211. Berwanger O, de Barros E Silva PGM, Barbosa RR, et al. Atorvastatin for high-risk statin-naïve patients undergoing noncardiac surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) randomized trial. Am Heart J. 2017; 184: 88–96.
  212. Sanders RD, Nicholson A, Lewis SR, et al. Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. Cochrane Database Syst Rev. 2013(7): CD009971.
  213. Putzu A, de Carvalho E Silva CM, de Almeida JP, et al. Perioperative statin therapy in cardiac and non-cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. Ann Intensive Care. 2018; 8(1): 95.
  214. Wesselink EM, Kappen TH, Torn HM, et al. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anaesth. 2018; 121(4): 706–721.
  215. Shiffermiller JF, Monson BJ, Vokoun CW, et al. Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI). J Hosp Med. 2018; 13(10): 661–667.
  216. Roshanov PS, Rochwerg B, Patel A, et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: an analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2017; 126(1): 16–27.
  217. Hollmann C, Fernandes NL, Biccard BM. A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery. Anesth Analg. 2018; 127(3): 678–687.
  218. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  219. Legrand M, Futier E, Leone M, et al. Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial). Trials. 2019; 20(1): 160.
  220. Wijeysundera DN, Beattie WS. Calcium channel blockers for reducing cardiac morbidity after noncardiac surgery: a meta-analysis. Anesth Analg. 2003; 97(3): 634–641.
  221. Kertai MD, Westerhout CM, Varga KS, et al. Dihydropiridine calcium-channel blockers and perioperative mortality in aortic aneurysm surgery. Br J Anaesth. 2008; 101(4): 458–465.
  222. Oliver MF, Goldman L, Julian DG, et al. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology. 1999; 91(4): 951–961.
  223. Devereaux PJ, Mrkobrada M, Sessler DI, et al. Clonidine in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370(16): 1504–1513.
  224. Hager B, Betschart M, Krapf R. Effect of postoperative intravenous loop diuretic on renal function after major surgery. Schweiz Med Wochenschr. 1996; 126(16): 666–673.
  225. Arora P, Pourafkari L, Visnjevac O, et al. Preoperative serum potassium predicts the clinical outcome after non-cardiac surgery. Clin Chem Lab Med. 2017; 55(1): 145–153.
  226. Tagawa M, Ogata Ai, Hamano T. Pre- and/or intra-operative prescription of diuretics, but not renin-angiotensin-system inhibitors, is significantly associated with acute kidney injury after non-cardiac surgery: a retrospective cohort study. PLoS One. 2015; 10(7): e0132507.
  227. Lo Sapio P, Gensini GF, Bevilacqua S, et al. The role of ivabradine in the incidence of perioperative coronary complications in patients undergoing vascular surgery. Int J Cardiol. 2013; 168(4): 4352–4353.
  228. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, et al. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019; 123(1): 27–36.
  229. Patoulias D, Manafis A, Mitas C, et al. Sodium-glucose cotransporter 2 inhibitors and the risk of diabetic ketoacidosis; from pathophysiology to clinical practice. Cardiovasc Hematol Disord Drug Targets. 2018; 18(2): 139–146.
  230. Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med. 1996; 335(23): 1713–1720.
  231. McGory ML, Maggard MA, Ko CY. A meta-analysis of perioperative beta blockade: what is the actual risk reduction? Surgery. 2005; 138(2): 171–179.
  232. Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology. 1998; 88(1): 7–17.
  233. Bouri S, Shun-Shin MJ, Cole GD, et al. Meta-analysis of secure randomised controlled trials of β-blockade to prevent perioperative death in non-cardiac surgery. Heart. 2014; 100(6): 456–464.
  234. Hajibandeh S, Hajibandeh S, Antoniou SA, et al. Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis. Br J Anaesth. 2017; 118(1): 11–21.
  235. Xia J, Qu Y, Yin C, et al. Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery. Cardiology. 2015; 131(1): 30–37.
  236. McEvoy MD, Gupta R, Koepke EJ, et al. Perioperative Quality Initiative Consensus Statement on postoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth. 2019; 122(5): 575–586.
  237. Ellenberger C, Tait G, Beattie WS. Chronic β blockade is associated with a better outcome after elective noncardiac surgery than acute β blockade: a single-center propensity-matched cohort study. Anesthesiology. 2011; 114(4): 817–823.
  238. Zaugg M, Bestmann L, Wacker J, et al. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebocontrolled, multicenter trial with 1-year follow-up. Anesthesiology. 2007; 107(1): 33–44.
  239. Faloye AO, Gebre MA, Bechtel AJ. Predicting cardiac risk in noncardiac surgery: a narrative review. J Anesth. 2021; 35(1): 122–129.
  240. Steffel J, Collins R, Antz M, et al. 2021 European hHeart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23(10): 1612–1676.
  241. Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019; 321(3): 277–287.
  242. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
  243. Devereaux PJ, Mrkobrada M, Sessler D, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370(16): 1494–1503.
  244. Graham MM, Sessler DI, Parlow JL, et al. Aspirin in patients with previous percutaneous coronary intervention undergoing noncardiac surgery. Ann Intern Med. 2018; 168(4): 237–244.
  245. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43(7): 561–632.
  246. Brouwer J, Nijenhuis V, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020; 383(15): 1447–1457.
  247. Koo BK, Kang J, Park KW, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021; 397(10293): 2487–2496.
  248. Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019; 381(21): 2032–2042.
  249. Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018; 392(10151): 940–949.
  250. Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019; 321(24): 2414–2427.
  251. Berger PB, Kleiman NS, Pencina MJ, et al. Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. JACC Cardiovasc Interv. 2010; 3(9): 920–927.
  252. Saia F, Belotti LM, Guastaroba P, et al. Risk of adverse cardiac and bleeding events following cardiac and noncardiac surgery in patients with coronary stent: how important is the interplay between stent type and time from stenting to surgery? Circ Cardiovasc Qual Outcomes. 2016; 9(1): 39–47.
  253. Huber KC, Evans MA, Bresnahan JF, et al. Outcome of noncardiac operations in patients with severe coronary artery disease successfully treated preoperatively with coronary angioplasty. Mayo Clin Proc. 1992; 67(1): 15–21.
  254. Egholm G, Kristensen S, Thim T, et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation. J Am Coll Cardiol. 2016; 68(24): 2622–2632.
  255. Holcomb CN, Graham LA, Richman JS, et al. The incremental risk of coronary stents on postoperative adverse events: a matched cohort study. Ann Surg. 2016; 263(5): 924–930.
  256. Mahmoud KD, Sanon S, Habermann EB, et al. Perioperative cardiovascular risk of prior coronary stent implantation among patients undergoing noncardiac surgery. J Am Coll Cardiol. 2016; 67(9): 1038–1049.
  257. Holcomb CN, Hollis RH, Graham LA, et al. Association of coronary stent indication with postoperative outcomes following noncardiac surgery. JAMA Surg. 2016; 151(5): 462–469.
  258. Rodriguez A, Guilera N, Mases A, et al. Management of antiplatelet therapy in patients with coronary stents undergoing noncardiac surgery: association with adverse events. Br J Anaesth. 2018; 120(1): 67–76.
  259. Armstrong EJ, Graham L, Waldo SW, et al. Patient and lesion-specific characteristics predict risk of major adverse cardiovascular events among patients with previous percutaneous coronary intervention undergoing noncardiac surgery. Catheter Cardiovasc Interv. 2017; 89(4): 617–627.
  260. Siller-Matula JM, Petre A, Delle-Karth G, et al. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care. 2017; 6(8): 753–770.
  261. Mehran R, Baber U, Steg PG, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013; 382(9906): 1714–1722.
  262. So DYF, Wells GA, Lordkipanidze M, Ruel M, Perrault LP, Yeong Chong A, et al. A randomized study of early vs. delayed coronary artery bypass surgery among patients with acute coronary syndromes treated with ticagrelor: the RAPID CABG study. http://clinicaltrialresults.org/wp-content/uploads/2021/11/So_RAPID_ CABG.pdf.
  263. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009; 120(25): 2577–2585.
  264. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–260.
  265. Valgimigli M, Frigoli E, Heg D, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021; 385(18): 1643–1655.
  266. Garot P, Morice MC, Tresukosol D, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015; 373(21): 2038–2047.
  267. Windecker S, Latib A, Kedhi E, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020; 382(13): 1208–1218.
  268. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
  269. Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022; 7(4): 407–417.
  270. Kim BK, Hong MK, Shin DH, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012; 60: 1340–1348.
  271. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310(23): 2510–2522.
  272. Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015; 36(20): 1252–1263.
  273. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012; 125(3): 505–513.
  274. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125(16): 2015–2026.
  275. Han Y, Xu B, Xu K, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent: randomized substudy of the I-LOVE-IT 2 trial. Circ Cardiovasc Interv. 2016; 9(2): e003145.
  276. Hong SJ, Shin DH, Kim JS, et al. IVUS-XPL Investigators. 6-month versus 12-month dual-antiplatelet therapy following long everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JACC Cardiovasc Interv. 2016; 9(14): 1438–1446.
  277. Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018; 391(10127): 1274–1284.
  278. Kedhi E, Fabris E, van der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018; 363: k3793.
  279. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
  280. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
  281. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7): 494–502.
  282. Sullivan AE, Nanna MG, Wang TY, et al. Bridging antiplatelet therapy after percutaneous coronary intervention: JACC review topic of the week. J Am Coll Cardiol. 2021; 78(15): 1550–1563.
  283. Angheloiu GO, Gugiu GB, Ruse C, et al. Ticagrelor removal from human blood. JACC Basic Transl Sci. 2017; 2(2): 135–145.
  284. Bhatt DL, Pollack CV, Weitz JI, et al. Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med. 2019; 380(19): 1825–1833.
  285. Mahla E, Metzler H, Bornemann-Cimenti H, et al. Platelet inhibition and bleeding in patients undergoing non-cardiac surgery-the BIANCA Observational Study. Thromb Haemost. 2018; 118(5): 864–872.
  286. Mahla E, Tantry US, Prüller F, et al. Is there a role for preoperative platelet function testing in patients undergoing cardiac surgery during antiplatelet therapy? Circulation. 2018; 138(19): 2145–2159.
  287. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv. 2012; 5(2): 261–269.
  288. Windecker S, Lopes R, Massaro T, et al. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated medically or with percutaneous coronary intervention or undergoing elective percutaneous coronary intervention. Circulation. 2019; 140(23): 1921–1932.
  289. Généreux P, Rutledge DR, Palmerini T, et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from the xience v coronary stent system trials. Circ Cardiovasc Interv. 2015; 8(5): e001362.
  290. Beyer-Westendorf J, Gelbricht V, Förster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014; 35(28): 1888–1896.
  291. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143(5): e35–e71.
  292. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015; 373(9): 823–833.
  293. Kuo HC, Liu FL, Chen JT, et al. Thromboembolic and bleeding risk of periprocedural bridging anticoagulation: A systematic review and meta-analysis. Clin Cardiol. 2020; 43(5): 441–449.
  294. Kovacs MJ, Wells PS, Anderson DR, et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ. 2021; 373: n1205.
  295. Caldeira D, David C, Santos AT, et al. Efficacy and safety of low molecular weight heparin in patients with mechanical heart valves: systematic review and meta-analysis. J Thromb Haemost. 2014; 12(5): 650–659.
  296. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013; 368(22): 2084–2093.
  297. Sant'anna RT, Leiria TL, Nascimento T, et al. Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: reappraisal after the BRUISE study. Pacing Clin Electrophysiol. 2015; 38(4): 417–423.
  298. Eichhorn W, Barsukov E, Al-Dam A, et al. Postoperative bleeding risk for cutaneous surgery in the head and neck region with continued phenprocoumon therapy. J Craniomaxillofac Surg. 2014; 42(5): 608–611.
  299. Nandoe Tewarie RDS, Bartels RH. The perioperative use of oral anticoagulants during surgical procedures for carpal tunnel syndrome. A preliminary study. Acta Neurochir (Wien). 2010; 152(7): 1211–1213.
  300. Doherty JU, Gluckman TyJ, Hucker WJ, et al. 2017 ACC Expert Consensus Decision Pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017; 69(7): 871–898.
  301. Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016; 116(5): 879–890.
  302. Levy JH, Ageno W, Chan NC, et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016; 14(3): 623–627.
  303. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017; 377(5): 431–441.
  304. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor xa inhibitors. N Engl J Med. 2019; 380(14): 1326–1335.
  305. Majeed A, Ågren A, Holmström M, et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood. 2017; 130(15): 1706–1712.
  306. Healey JS, Eikelboom J, Yang S, et al. RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012; 126(3): 343–348.
  307. Garcia D, Alexander JH, Wallentin L, et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014; 124(25): 3692–3698.
  308. Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014; 129(18): 1850–1859.
  309. Shaw JR, Li Na, Vanassche T, et al. Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure. Blood Adv. 2020; 4(15): 3520–3527.
  310. Godier A, Dincq AS, Martin AC, et al. Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017; 38(31): 2431–2439.
  311. Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med. 2019; 179(11): 1469–1478.
  312. Colonna P, von Heymann C, Santamaria A, et al. Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study. Clin Cardiol. 2020; 43(7): 769–780.
  313. Albaladejo P, Pernod G, Godier A, et al. Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) - September 2016. Anaesth Crit Care Pain Med. 2018; 37(4): 391–399.
  314. Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015; 40(3): 182–212.
  315. Johnston S. An evidence summary of the management of patients taking direct oral anticoagulants (DOACs) undergoing dental surgery. Int J Oral Maxillofac Surg. 2016; 45(5): 618–630.
  316. Sivolella S, De Biagi M, Brunello G, et al. Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants. Odontology. 2015; 103(3): 258–263.
  317. Ockerman A, Vanhaverbeke M, Miclotte I, et al. Tranexamic acid to reduce bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants: design and rationale of the EXTRACT-NOAC trial. Br J Oral Maxillofac Surg. 2019; 57(10): 1107–1112.
  318. Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020; 382(18): 1696–1707.
  319. Xu K, Chan NC, Ibrahim Q, et al. Reduction in mortality following elective major hip and knee surgery: a systematic review and meta-analysis. Thromb Haemost. 2019; 119(4): 668–674.
  320. Smilowitz NR, Gupta N, Guo Yu, et al. Trends in perioperative venous thromboembolism associated with major noncardiac surgery. TH Open. 2017; 1(2): e82–e91.
  321. Klemen ND, Feingold PL, Hashimoto B, et al. Mortality risk associated with venous thromboembolism: a systematic review and Bayesian meta-analysis. Lancet Haematol. 2020; 7(8): e583–e593.
  322. Gangireddy C, Rectenwald JR, Upchurch GR, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007; 45(2): 335–341.
  323. Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010; 199(1 Suppl): S3–10.
  324. Obi AT, Pannucci CJ, Nackashi A, et al. Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients. JAMA Surg. 2015; 150(10): 941–948.
  325. Lobastov K, Barinov V, Schastlivtsev I, et al. Validation of the Caprini risk assessment model for venous thromboembolism in high-risk surgical patients in the background of standard prophylaxis. J Vasc Surg Venous Lymphat Disord. 2016; 4(2): 153–160.
  326. Hachey KJ, Hewes PD, Porter LP, et al. Caprini venous thromboembolism risk assessment permits selection for postdischarge prophylactic anticoagulation in patients with resectable lung cancer. J Thorac Cardiovasc Surg. 2016; 151(1): 37–44.e1.
  327. Sterbling HM, Rosen AK, Hachey KJ, et al. Caprini risk model decreases venous thromboembolism rates in thoracic surgery cancer patients. Ann Thorac Surg. 2018; 105(3): 879–885.
  328. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(Suppl 2): e278S–e325S.
  329. Faraoni D, Comes RF, Geerts W, et al. European guidelines on perioperative venous thromboembolism prophylaxis: neurosurgery. Eur J Anaesthesiol. 2018; 35(2): 90–95.
  330. Kozek-Langenecker S, Fenger-Eriksen C, Thienpont E, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Surgery in the elderly. Eur J Anaesthesiol. 2018; 35(2): 116–122.
  331. Venclauskas L, Maleckas A, Arcelus JI, et al. ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Surgery in the obese patient. Eur J Anaesthesiol. 2018; 35(2): 147–153.
  332. Afshari A, Ageno W, Ahmed A, et al. European Guidelines on perioperative venous thromboembolism prophylaxis: Executive summary. Eur J Anaesthesiol. 2018; 35(2): 77–83.
  333. Cimminiello C, Prandoni P, Agnelli G, et al. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med. 2017; 12(8): 1291–1305.
  334. Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010; 363(26): 2487–2498.
  335. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009; 361(6): 594–604.
  336. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26): 2776–2786.
  337. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26): 2765–2775.
  338. Friedman RJ, Dahl OE, Rosencher N, et al. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010; 126(3): 175–182.
  339. Kawai Y, Fuji T, Fujita S, et al. Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials. Thromb J. 2016; 14: 48.
  340. Petersen PB, Kehlet H, Jørgensen CC, et al. Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group. Safety of in-hospital only thromboprophylaxis after fast-track total hip and knee arthroplasty: a prospective follow-up study in 17,582 procedures. Thromb Haemost. 2018; 118(12): 2152–2161.
  341. Wilson DGG, Poole WEC, Chauhan SK, et al. Systematic review of aspirin for thromboprophylaxis in modern elective total hip and knee arthroplasty. Bone Joint J. 2016; 98-B(8): 1056–1061.
  342. Jenny JY, Pabinger I, Samama CM, et al. ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: Aspirin. Eur J Anaesthesiol. 2018; 35(2): 123–129.
  343. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018; 378(8): 699–707.
  344. Cassidy MR, Rosenkranz P, McAneny D. Reducing postoperative venous thromboembolism complications with a standardized risk-stratified prophylaxis protocol and mobilization program. J Am Coll Surg. 2014; 218(6): 1095–1104.
  345. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011; 378(9800): 1396–1407.
  346. Baron DM, Franchini M, Goobie SM, et al. Patient blood management during the COVID-19 pandemic: a narrative review. Anaesthesia. 2020; 75(8): 1105–1113.
  347. Muñoz M, Gómez-Ramírez S, Campos A, et al. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus. 2015; 13(3): 370–379.
  348. von Heymann C, Kaufner L, Sander M, et al. Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery? J Thorac Cardiovasc Surg. 2016; 152(5): 1412–1420.
  349. Rössler J, Schoenrath F, Seifert B, et al. Iron deficiency is associated with higher mortality in patients undergoing cardiac surgery: a prospective study. Br J Anaesth. 2020; 124(1): 25–34.
  350. Althoff FC, Neb H, Herrmann E, et al. Multimodal patient blood management program based on a three-pillar strategy: a systematic review and meta-analysis. Ann Surg. 2019; 269(5): 794–804.
  351. Meybohm P, Herrmann E, Steinbicker AU, et al. Patient blood management is associated with a substantial reduction of red blood cell utilization and safe for patient’s outcome: a prospective, multicenter cohort study with a noninferiority design. Ann Surg. 2016; 264: 203–211.
  352. Frew N, Alexander D, Hood J, et al. Impact of a blood management protocol on transfusion rates and outcomes following total hip and knee arthroplasty. Ann R Coll Surg Engl. 2016; 98(6): 380–386.
  353. Leahy MF, Hofmann A, Towler S, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. Transfusion. 2017; 57(6): 1347–1358.
  354. So-Osman C, Nelissen RG, Koopman-van Gemert AW, et al. Patient blood management in elective total hip- and knee-replacement surgery (Part 1): a randomized controlled trial on erythropoietin and blood salvage as transfusion alternatives using a restrictive transfusion policy in erythropoietin-eligible patients. Anesthesiology. 2014; 120(4): 839–851.
  355. Theusinger OM, Kind SL, Seifert B, et al. Patient blood management in orthopaedic surgery: a four-year follow-up of transfusion requirements and blood loss from 2008 to 2011 at the Balgrist University Hospital in Zurich, Switzerland. Blood Transfus. 2014; 12(2): 195–203.
  356. Froessler B, Palm P, Weber I, et al. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016; 264(1): 41–46.
  357. Triphaus C, Judd L, Glaser P, et al. Effectiveness of preoperative iron supplementation in major surgical patients with iron deficiency. Ann Surg. 2019; 274(3): e212–e219.
  358. Cappellini MD, Comin-Colet J, Francisco Ade, et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017; 92(10): 1068–1078.
  359. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 2014; 12(3): 296–300.
  360. Richards T, Baikady RR, Clevenger B, et al. Preoperative intravenous iron to treat anaemia before major abdominal surgery (PREVENTT): a randomised, double-blind, controlled trial. Lancet. 2020; 396(10259): 1353–1361.
  361. Kaufner L, von Heymann C, Henkelmann A, et al. Erythropoietin plus iron versus control treatment including placebo or iron for preoperative anaemic adults undergoing non-cardiac surgery. Cochrane Database Syst Rev. 2020; 8: CD012451.
  362. Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017; 72(2): 233–247.
  363. World Health Assembly. Availability, safety and quality of blood products. http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_R12-en.pdf (October 27, 2017).
  364. Kotzé A, Harris A, Baker C, et al. British Committee for Standards in Haematology Guidelines on the identification and management of pre-operative anaemia. Br J Haematol. 2015; 171(3): 322–331.
  365. Koch CG, Reineks EZ, Tang AS, et al. Contemporary bloodletting in cardiac surgical care. Ann Thorac Surg. 2015; 99(3): 779–784.
  366. Riessen R, Behmenburg M, Blumenstock G, et al. A simple "blood-saving bundle" reduces diagnostic blood loss and the transfusion rate in mechanically ventilated patients. PLoS One. 2015; 10(9): e0138879.
  367. Shander A, Kaplan LJ, Harris MT, et al. Topical hemostatic therapy in surgery: bridging the knowledge and practice gap. J Am Coll Surg. 2014; 219(3): 570–579.e4.
  368. Menkis AH, Martin J, Cheng DCH, et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila). 2012; 7(4): 229–241.
  369. Anastasiadis K, Murkin J, Antonitsis P, et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS). Interact Cardiovasc Thorac Surg. 2016; 22(5): 647–662.
  370. Weber CF, Görlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012; 117(3): 531–547.
  371. Weber CF, Zacharowski K, Meybohm P, et al. Hemotherapy algorithms for coagulopathic cardiac surgery patients. Clin Lab. 2014; 60(6): 1059–1063.
  372. Muñoz M, Gómez-Ramírez S, Kozek-Langeneker S. Pre-operative haematological assessment in patients scheduled for major surgery. Anaesthesia. 2016; 71(Suppl 1): 19–28.
  373. Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30(6): 270–382.
  374. Meybohm P, Zacharowski K, Weber CF. Point-of-care coagulation management in intensive care medicine. Crit Care. 2013; 17(2): 218.
  375. Ker K, Edwards P, Perel P, et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012; 344: e3054.
  376. Devereaux PJ, Marcucci M, Balasubramanian K, et al. Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022; 386(21): 1986–1997.
  377. Meybohm P, Choorapoikayil S, Wessels A, et al. Washed cell salvage in surgical patients: A review and meta-analysis of prospective randomized trials under PRISMA. Medicine (Baltimore). 2016; 95(31): e4490.
  378. Santos AA, Silva JP, Silva Ld, et al. Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: a systematic review. Rev Bras Cir Cardiovasc. 2014; 29(4): 606–621.
  379. Haensig M, Kempfert J, Kempfert PM, et al. Thrombelastometry guided blood-component therapy after cardiac surgery: a randomized study. BMC Anesthesiol. 2019; 19(1): 201.
  380. Dias JD, Sauaia A, Achneck HE, et al. Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis. J Thromb Haemost. 2019; 17(6): 984–994.
  381. Chutipongtanate A, Yasaeng C, Virankabutra T, et al. Systematic comparison of four point-of-care methods versus the reference laboratory measurement of hemoglobin in the surgical ICU setting: a cross-sectional method comparison study. BMC Anesthesiol. 2020; 20(1): 92.
  382. Terada R, Ikeda T, Mori Y, et al. Comparison of two point of care whole blood coagulation analysis devices and conventional coagulation tests as a predicting tool of perioperative bleeding in adult cardiac surgery — a pilot prospective observational study in Japan. Transfusion. 2019; 59(11): 3525–3535.
  383. Cohen J, Scorer T, Wright Z, et al. A prospective evaluation of thromboelastometry (ROTEM) to identify acute traumatic coagulopathy and predict massive transfusion in military trauma patients in Afghanistan. Transfusion. 2019; 59(S2): 1601–1607.
  384. Yates J, Perelman I, Khair S, et al. Exclusion criteria and adverse events in perioperative trials of tranexamic acid: a systematic review and meta-analysis. Transfusion. 2019; 59(2): 806–824.
  385. CRASH-3 trial collaborators. Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial. Lancet. 2019; 394(10210): 1713–1723.
  386. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020; 395(10241): 1927–1936.
  387. Mukhopadhyay A, Yip HS, Prabhuswamy D, et al. The use of a blood conservation device to reduce red blood cell transfusion requirements: a before and after study. Crit Care. 2010; 14: R7.
  388. Peruzzi WT, Parker MA, Lichtenthal PR, et al. A clinical evaluation of a blood conservation device in medical intensive care unit patients. Crit Care Med. 1993; 21(4): 501–506.
  389. Kataife ED, Said S, Braun J, et al. The Haemostasis Traffic Light, a user-centred coagulation management tool for acute bleeding situations: a simulation-based randomised dual-centre trial. Anaesthesia. 2021; 76(7): 902–910.
  390. Goodnough LT, Shieh L, Hadhazy E, et al. Improved blood utilization using real-time clinical decision support. Transfusion. 2014; 54(5): 1358–1365.
  391. Oliver JC, Griffin RL, Hannon T, et al. The success of our patient blood management program depended on an institution-wide change in transfusion practices. Transfusion. 2014; 54(10 Pt 2): 2617–2624.
  392. Kaserer A, Rössler J, Braun J, et al. Impact of a patient blood management monitoring and feedback programme on allogeneic blood transfusions and related costs. Anaesthesia. 2019; 74(12): 1534–1541.
  393. Sardar M, Azharuddin M, Subedi A, et al. Improving blood transfusion practices in a community hospital setting: our experience with real-time clinical decision support. Med Sci (Basel). 2018; 6(3).
  394. Jenkins I, Doucet JJ, Clay B, et al. Transfusing wisely: clinical decision support improves blood transfusion practices. Jt Comm J Qual Patient Saf. 2017; 43(8): 389–395.
  395. Staples S, Salisbury RA, King AJ, et al. How do we use electronic clinical decision support and feedback to promote good transfusion practice. Transfusion. 2020; 60(8): 1658–1665.
  396. Derzon JH, Clarke N, Alford A, et al. Restrictive transfusion strategy and clinical decision support practices for reducing RBC transfusion overuse. Am J Clin Pathol. 2019; 152(5): 544–557.
  397. Dawood MM, Gutpa DK, Southern J, et al. Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention. Int J Cardiol. 1996; 57(1): 37–44.
  398. Eagle KA, Rihal CS, Mickel MC, et al. Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation. 1997; 96(6): 1882–1887.
  399. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004; 351(27): 2795–2804.
  400. Wong EYW, Lawrence HP, Wong DT. The effects of prophylactic coronary revascularization or medical management on patient outcomes after noncardiac surgery — a meta-analysis. Can J Anaesth. 2007; 54(9): 705–717.
  401. Feng B, Lin J, Jin J, et al. The effect of previous coronary artery revascularization on the adverse cardiac events ninety days after total joint arthroplasty. J Arthroplasty. 2018; 33(1): 235–240.
  402. Maron D, Hochman J, Reynolds H, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020; 382(15): 1395–1407.
  403. Bainey KR, Alemayehu W, Welsh RC, et al. Long-term clinical outcomes following revascularization in high-risk coronary anatomy patients with stable ischemic heart disease. J Am Heart Assoc. 2021; 10(1): e018104.
  404. Windecker S, Neumann FJ, Jüni P, et al. Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 204–212.
  405. Räber L, Mintz G, Koskinas K, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. EuroIntervention. 2018; 14(6): 656–677.
  406. Johnson TW, Räber L, Di Mario C, et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. EuroIntervention. 2019; 15(5): 434–451.
  407. Richardt G, Abdelghani M, Allali A, et al. Polymer-free drug-coated vs. bare-metal coronary stents in patients undergoing non-cardiac surgery: a subgroup analysis of the LEADERS FREE trial. Clin Res Cardiol. 2021; 110(2): 162–171.
  408. Cassese S, Belle L, Ndrepepa G, et al. Deferred vs immediate stenting in primary percutaneous coronary intervention: a collaborative meta-analysis of randomized trials with cardiac magnetic resonance imaging data. Can J Cardiol. 2018; 34(12): 1573–1580.
  409. Belle L, Motreff P, Mangin L, et al. MIMI Investigators*. Comparison of immediate with delayed stenting using the minimalist immediate mechanical intervention approach in acute ST-segment-elevation myocardial infarction: the MIMI study. Circ Cardiovasc Interv. 2016; 9(3): e003388.
  410. Hammill BG, Curtis LH, Bennett-Guerrero E, et al. Impact of heart failure on patients undergoing major noncardiac surgery. Anesthesiology. 2008; 108(4): 559–567.
  411. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med. 1977; 297(16): 845–850.
  412. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
  413. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100(10): 1043–1049.
  414. Flu WJ, van Kuijk JP, Hoeks SE, et al. Prognostic implications of asymptomatic left ventricular dysfunction in patients undergoing vascular surgery. Anesthesiology. 2010; 112(6): 1316–1324.
  415. Cohn SL. Preoperative evaluation for noncardiac surgery. Ann Intern Med. 2016; 165(11): ITC81–ITC96.
  416. Smilowitz NR, Banco D, Katz SD, et al. Association between heart failure and perioperative outcomes in patients undergoing non-cardiac surgery. Eur Heart J Qual Care Clin Outcomes. 2021; 7(1): 68–75.
  417. Lerman BJ, Popat RA, Assimes TL, et al. Association between heart failure and postoperative mortality among patients undergoing ambulatory noncardiac surgery. JAMA Surg. 2019; 154(10): 907–914.
  418. Dhillon A, Khanna A, Randhawa MS, et al. Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery. Heart. 2016; 102(20): 1627–1632.
  419. Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2011; 24(5): 473–498.
  420. Kormos RL, Cowger J, Pagani FD, et al. The Society of Thoracic Surgeons Intermacs database annual report: Evolving indications, outcomes, and scientific partnerships. J Heart Lung Transplant. 2019; 38(2): 114–126.
  421. Roberts SM, Hovord DG, Kodavatiganti R, et al. Ventricular assist devices and non-cardiac surgery. BMC Anesthesiol. 2015; 15: 185.
  422. Rodseth RN, Biccard BM, Le Manach Y, et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol. 2014; 63(2): 170–180.
  423. Karthikeyan G, Moncur RA, Levine O, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol. 2009; 54(17): 1599–1606.
  424. Agarwal S, Rajamanickam A, Bajaj NS, et al. Impact of aortic stenosis on postoperative outcomes after noncardiac surgeries. Circ Cardiovasc Qual Outcomes. 2013; 6(2): 193–200.
  425. Taniguchi T, Morimoto T, Shiomi H, et al. Elective non-cardiac surgery in patients with severe aortic stenosis — observations from the CURRENT AS registry. Circ J. 2020; 84(7): 1173–1182.
  426. Luis SA, Dohaei A, Chandrashekar P, et al. Impact of aortic valve replacement for severe aortic stenosis on perioperative outcomes following major noncardiac surgery. Mayo Clin Proc. 2020; 95(4): 727–737.
  427. Okuno T, Yahagi K, Horiuchi Yu, et al. The role of transcatheter aortic valve replacement in the patients with severe aortic stenosis requiring major non-cardiac surgery. Cardiovasc Interv Ther. 2019; 34(4): 345–351.
  428. Calleja AM, Dommaraju S, Gaddam R, et al. Cardiac risk in patients aged >75 years with asymptomatic, severe aortic stenosis undergoing noncardiac surgery. Am J Cardiol. 2010; 105(8): 1159–1163.
  429. Sohrabi B, Kazemi B, Mehryar A, et al. Correlation between pulmonary artery pressure measured by echocardiography and right heart catheterization in patients with rheumatic mitral valve stenosis (a prospective study). Echocardiography. 2016; 33(1): 7–13.
  430. Bajaj NS, Agarwal S, Rajamanickam A, et al. Impact of severe mitral regurgitation on postoperative outcomes after noncardiac surgery. Am J Med. 2013; 126(6): 529–535.
  431. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018; 379(24): 2307–2318.
  432. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015; 36(44): 3075–3128.
  433. Polanczyk CA, Goldman L, Marcantonio ER, et al. Supraventricular arrhythmia in patients having noncardiac surgery: clinical correlates and effect on length of stay. Ann Intern Med. 1998; 129(4): 279–285.
  434. van Diepen S, Bakal JA, McAlister FA, et al. Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38 047 patients. Circulation. 2011; 124(3): 289–296.
  435. Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol. 2003; 14(Suppl 9): S87–S95.
  436. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020; 41(5): 655–720.
  437. Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentrant tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. The Atakr Multicenter Investigators Group. Circulation. 1999; 99(2): 262–270.
  438. Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation. 1994; 90(3): 1262–1278.
  439. Katritsis DG, Zografos T, Katritsis GD, et al. Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial. Europace. 2017; 19(4): 602–606.
  440. Pappone C, Vicedomini G, Manguso F, et al. Wolff-Parkinson-White syndrome in the era of catheter ablation: insights from a registry study of 2169 patients. Circulation. 2014; 130(10): 811–819.
  441. Spector P, Reynolds MR, Calkins H, et al. Meta-analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol. 2009; 104(5): 671–677.
  442. Potpara TS, Polovina MM, Marinkovic JM, et al. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol. 2013; 168(5): 4744–4749.
  443. Mujović N, Dobrev D, Marinković M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res. 2020; 151: 104521.
  444. Dan GA, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018; 20(5): 731–732an.
  445. Ellenbogen KA, Dias VC, Plumb VJ, et al. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: A multicenter study. J Am Coll Cardiol. 1991; 18(4): 891–897.
  446. Phillips BG, Gandhi AJ, Sanoski CA, et al. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 1997; 17: 1238–1245.
  447. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989; 63(13): 925–929.
  448. Sethi NJ, Nielsen EE, Safi S, et al. Digoxin for atrial fibrillation and atrial flutter: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS One. 2018; 13(3): e0193924.
  449. Delle Karth G, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med. 2001; 29(6): 1149–1153.
  450. Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart. 1998; 79(6): 568–575.
  451. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation. 2000; 102(19): 2385–2390.
  452. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. J Am Coll Cardiol. 1998; 31(6): 1414–1419.
  453. Bianconi L, Castro A, Dinelli M, et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur Heart J. 2000; 21(15): 1265–1273.
  454. Kerola T, Dewland TA, Vittinghoff E, et al. Modifiable predictors of ventricular ectopy in the community. J Am Heart Assoc. 2018; 7(22): e010078.
  455. Yang J, Dudum R, Mandyam MC, et al. Characteristics of unselected high-burden premature ventricular contraction patients. Pacing Clin Electrophysiol. 2014; 37(12): 1671–1680.
  456. Parreira L, Marinheiro R, Amador P, et al. Frequent premature ventricular contractions. Association of burden and complexity with prognosis according to the presence of structural heart disease. Ann Noninvasive Electrocardiol. 2021; 26(1): e12800.
  457. Agarwal V, Vittinghoff E, Whitman IR, et al. Relation between ventricular premature complexes and incident heart failure. Am J Cardiol. 2017; 119(8): 1238–1242.
  458. Dukes JW, Dewland TA, Vittinghoff E, et al. Ventricular ectopy as a predictor of heart failure and death. J Am Coll Cardiol. 2015; 66(2): 101–109.
  459. Marcus GM. Evaluation and management of premature ventricular complexes. Circulation. 2020; 141(17): 1404–1418.
  460. Mukharji J, Rude R, Poole W, et al. Risk factors for sudden death after acute myocardial infarction: Two-year follow-up. Am J Cardiol. 1984; 54(1): 31–36.
  461. Chen J, Johnson G, Hellkamp AS, et al. Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol. 2013; 61(21): 2161–2168.
  462. Makimoto H, Zielke S, Clasen L, et al. Clinical significance of precedent asymptomatic non-sustained ventricular tachycardias on subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients. Eur J Med Res. 2020; 25(1): 5.
  463. Sánchez Muñoz JJ, García-Alberola A, Martínez-Sánchez J, et al. Premature ventricular complexes as a trigger for ventricular fibrillation. Revi Esp Cardiol. 2010; 63(7): 798–801.
  464. Kakishita M, Kurita T, Matsuo K, et al. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy. J Am Coll Cardiol. 2000; 36(5): 1646–1653.
  465. Srivathsan K, Gami AS, Ackerman MJ, et al. Treatment of ventricular fibrillation in a patient with prior diagnosis of long QT syndrome: importance of precise electrophysiologic diagnosis to successfully ablate the trigger. Heart Rhythm. 2007; 4(8): 1090–1093.
  466. Almendral J, Villacastin JP, Arenal A, et al. Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension. Am J Cardiol. 1995; 76(13): 60D–63D.
  467. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015; 36(41): 2793–2867.
  468. Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006; 295(2): 165–171.
  469. Brodine WN, Tung RT, Lee JK, et al. Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol. 2005; 96(5): 691–695.
  470. Tilz RR, Lenarczyk R, Scherr D, et al. Management of ventricular tachycardia in the ablation era: results of the European Heart Rhythm Association Survey. Europace. 2018; 20(1): 209–213.
  471. Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace. 2019; 21(8): 1143–1144.
  472. Scheuermeyer FX, Grafstein E, Stenstrom R, et al. Thirty-day and 1-year outcomes of emergency department patients with atrial fibrillation and no acute underlying medical cause. Ann Emerg Med. 2012; 60(6): 755–765.e2.
  473. Bonfanti L, Annovi A, Sanchis-Gomar F, et al. Effectiveness and safety of electrical cardioversion for acute-onset atrial fibrillation in the emergency department: a real-world 10-year single center experience. Clin Exp Emerg Med. 2019; 6(1): 64–69.
  474. Kheiri B, Barbarawi M, Zayed Y, et al. Antiarrhythmic drugs or catheter ablation in the management of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm Electrophysiol. 2019; 12(11): e007600.
  475. Santangeli P, Muser D, Maeda S, et al. Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials. Heart Rhythm. 2016; 13(7): 1552–1559.
  476. Martinez BK, Baker WL, Konopka A, et al. Systematic review and meta-analysis of catheter ablation of ventricular tachycardia in ischemic heart disease. Heart Rhythm. 2020; 17(1): e206–e219.
  477. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med. 2007; 357(26): 2657–2665.
  478. Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med. 2016; 375(2): 111–121.
  479. Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010; 375(9708): 31–40.
  480. Briceño DF, Gupta T, Romero J, et al. Catheter ablation of ventricular tachycardia in nonischemic cardiomyopathy: A propensity score-matched analysis of in-hospital outcomes in the United States. J Cardiovasc Electrophysiol. 2018; 29(5): 771–779.
  481. Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021; 42(35): 3427–3520.
  482. Martí-Almor J, Cladellas M, Bazán V, et al. [Novel predictors of progression of atrioventricular block in patients with chronic bifascicular block]. Rev Esp Cardiol. 2010; 63(4): 400–408.
  483. Santini M, Castro A, Giada F, et al. Prevention of syncope through permanent cardiac pacing in patients with bifascicular block and syncope of unexplained origin: the PRESS study. Circ Arrhythm Electrophysiol. 2013; 6(1): 101–107.
  484. Stone ME, Salter B, Fischer A. Perioperative management of patients with cardiac implantable electronic devices. Br J Anaesth. 2011; 107(Suppl 1): i16–i26.
  485. Cardiac implantable electronic device management (corrected). Anesthesiology. 2020; 132(2): 225–252.
  486. Gifford J, Larimer K, Thomas C, et al. ICD-ON registry for perioperative management of CIEDs: most require no change. Pacing Clin Electrophysiol. 2017; 40(2): 128–134.
  487. Mahlow WJ, Craft RM, Misulia NL, et al. A perioperative management algorithm for cardiac rhythm management devices: the PACED-OP protocol. Pacing Clin Electrophysiol. 2013; 36(2): 238–248.
  488. Neubauer H, Wellmann M, Herzog-Niescery J, et al. Comparison of perioperative strategies in ICD patients: The perioperative ICD management study (PIM study). Pacing Clin Electrophysiol. 2018; 41(11): 1536–1542.
  489. Feldman JB, Stone ME. Anesthesia teams managing pacemakers and ICDs for the perioperative period: enhanced patient safety and improved workflows. Curr Opin Anaesthesiol. 2020; 33(3): 441–447.
  490. Mickus GJ, Soliman GI, Reed RR, et al. Perioperative management of a leadless pacemaker: the paucity of evidence-based guidelines. J Cardiothorac Vasc Anesth. 2016; 30(6): 1594–1598.
  491. Karuppiah S, Prielipp R, Banik RK. Anesthetic consideration for patients with micra leadless pacemaker. Ann Card Anaesth. 2020; 23(4): 493–495.
  492. Gifford J, Larimer K, Thomas C, et al. Randomized controlled trial of perioperative ICD management: magnet application versus reprogramming. Pacing Clin Electrophysiol. 2014; 37(9): 1219–1224.
  493. Winter J, Kohlmeier A, Shin DI, et al. Subcutaneous implantable cardioverter-defibrillators and sternal wires: a cautionary tale. Circ Arrhythm Electrophysiol. 2014; 7(5): 986–987.
  494. Schulman PM, Treggiari MM, Yanez ND, et al. Electromagnetic interference with protocolized electrosurgery dispersive electrode positioning in patients with implantable cardioverter defibrillators. Anesthesiology. 2019; 130(4): 530–540.
  495. Baeg MKi, Kim SW, Ko SH, et al. Endoscopic electrosurgery in patients with cardiac implantable electronic devices. Clin Endosc. 2016; 49(2): 176–181.
  496. Mangar D, Atlas GM, Kane PB. Electrocautery-induced pacemaker malfunction during surgery. Can J Anaesth. 1991; 38(5): 616–618.
  497. Rozner MA. Review of electrical interference in implanted cardiac devices. Pacing Clin Electrophysiol. 2003; 26(4 Pt 1): 923–925.
  498. de Cock CC, Spruijt HJ, van Campen LM, et al. Electromagnetic interference of an implantable loop recorder by commonly encountered electronic devices. Pacing Clin Electrophysiol. 2000; 23(10 Pt 1): 1516–1518.
  499. Suarez-Fuster L, Oh C, Baranchuk A. Transcutaneous electrical nerve stimulation electromagnetic interference in an implantable loop recorder. J Arrhythm. 2018; 34(1): 96–97.
  500. Gilboa SM, Salemi JL, Nembhard WN, et al. Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006. Circulation. 2010; 122(22): 2254–2263.
  501. Marelli AJ, Ionescu-Ittu R, Mackie AS, et al. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. Circulation. 2014; 130(9): 749–756.
  502. Maxwell BG, Wong JK, Kin C, et al. Perioperative outcomes of major noncardiac surgery in adults with congenital heart disease. Anesthesiology. 2013; 119(4): 762–769.
  503. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J. 2021; 42(6): 563–645.
  504. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34): 3165–3241.
  505. Ammash NM, Connolly HM, Abel MD, et al. Noncardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol. 1999; 33(1): 222–227.
  506. Faraoni D, Zurakowski D, Vo D, et al. Post-operative outcomes in children with and without congenital heart disease undergoing noncardiac surgery. J Am Coll Cardiol. 2016; 67(7): 793–801.
  507. Alonso-Gonzalez R, Borgia F, Diller GP, et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation. 2013; 127(8): 882–890.
  508. Maxwell BG, Posner KL, Wong JK, et al. Factors contributing to adverse perioperative events in adults with congenital heart disease: a structured analysis of cases from the closed claims project. Congenit Heart Dis. 2015; 10(1): 21–29.
  509. Lui GK, Saidi A, Bhatt AB, et al. Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2017; 136(20): e348–e392.
  510. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36(42): 2921–2964.
  511. Tuck BC, Townsley MM. Clinical update in pericardial diseases. J Cardiothorac Vasc Anesth. 2019; 33(1): 184–199.
  512. Ristić AD, Imazio M, Adler Y, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2014; 35(34): 2279–2284.
  513. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005; 127(6): 1952–1959.
  514. Canet J, Gallart L, Gomar C, et al. ARISCAT Group. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010; 113(6): 1338–1350.
  515. Edrich T, Sadovnikoff N. Anesthesia for patients with severe chronic obstructive pulmonary disease. Curr Opin Anaesthesiol. 2010; 23(1): 18–24.
  516. Chau EHL, Lam D, Wong J, et al. Obesity hypoventilation syndrome: a review of epidemiology, pathophysiology, and perioperative considerations. Anesthesiology. 2012; 117(1): 188–205.
  517. Kaw R, Gali B, Collop NA. Perioperative care of patients with obstructive sleep apnea. Curr Treat Options Neurol. 2011; 13(5): 496–507.
  518. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016; 37(1): 67–119.
  519. Bowker D, Banks D. Pulmonary hypertension in noncardiac surgical patients. In: Kaplan JA, Cronin B, Maus TM. ed. Essentials of Cardiac Anesthesia for Noncardiac Surgery. Elsevier, Philadelphia 2019: 138–164.
  520. Meyer S, McLaughlin VV, Seyfarth HJ, et al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J. 2013; 41(6): 1302–1307.
  521. Price LC, Montani D, Jaïs X, et al. Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension. Eur Respir J. 2010; 35(6): 1294–1302.
  522. Olsson KM, Halank M, Egenlauf B, et al. Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: updated recommendations from the Cologne Consensus Conference 2018. Int J Cardiol. 2018; 272S: 46–52.
  523. Pilkington SA, Taboada D, Martinez G. Pulmonary hypertension and its management in patients undergoing non-cardiac surgery. Anaesthesia. 2015; 70(1): 56–70.
  524. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022.
  525. Thunberg CA, Gaitan BD, Grewal A, et al. Pulmonary hypertension in patients undergoing cardiac surgery: pathophysiology, perioperative management, and outcomes. J Cardiothorac Vasc Anesth. 2013; 27(3): 551–572.
  526. Hayward CS, Kelly RP, Macdonald PS. Inhaled nitric oxide in cardiology practice. Cardiovasc Res. 1999; 43(3): 628–638.
  527. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013; 310(9): 959–968.
  528. Futier E, Lefrant JY, Guinot PG, et al. Effect of individualized vs standard blood pressure management strategies on postoperative organ dysfunction among high-risk patients undergoing major surgery: a randomized clinical trial. JAMA. 2017; 318(14): 1346–1357.
  529. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104.
  530. Howell SJ, Sear JW, Foëx P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth. 2004; 92(4): 570–583.
  531. Messina A, Robba C, Calabrò L, et al. Association between perioperative fluid administration and postoperative outcomes: a 20-year systematic review and a meta-analysis of randomized goal-directed trials in major visceral/noncardiac surgery. Crit Care. 2021; 25(1): 43.
  532. Jørgensen ME, Hlatky MA, Køber L, et al. β-blocker-associated risks in patients with uncomplicated hypertension undergoing noncardiac surgery. JAMA Intern Med. 2015; 175(12): 1923–1931.
  533. Marino KA, Little MA, Bursac Z, et al. The dilemma of immediate preoperative hypertension: to treat and operate, or to postpone surgery? J Clin Anesth. 2003; 15(3): 179–183.
  534. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33(13): 1635–1701.
  535. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO). The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39(9): 763–816.
  536. Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk). Circulation. 2018; 137(4): 338–350.
  537. Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018; 391(10117): 219–229.
  538. Ashton CM, Petersen NJ, Wray NP, et al. The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery. Ann Intern Med. 1993; 118(7): 504–510.
  539. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg. 2019; 58(1): S1–S109.e33.
  540. Brown LC, Powell JT, Thompson SG, et al. The UK EndoVascular Aneurysm Repair (EVAR) trials: randomised trials of EVAR versus standard therapy. Health Technol Assess. 2012; 16(9): 1–218.
  541. Paravastu SC, Jayarajasingam R, Cottam R, et al. Endovascular repair of abdominal aortic aneurysm. Cochrane Database Syst Rev. 2014(1): CD004178.
  542. Stather PW, Sidloff D, Dattani N, et al. Systematic review and meta-analysis of the early and late outcomes of open and endovascular repair of abdominal aortic aneurysm. Br J Surg. 2013; 100(7): 863–872.
  543. Eslami MH, Rybin DV, Doros G, et al. External validation of Vascular Study Group of New England risk predictive model of mortality after elective abdominal aorta aneurysm repair in the Vascular Quality Initiative and comparison against established models. J Vasc Surg. 2018; 67(1): 143–150.
  544. Bonaca MP, Bauersachs RM, Hiatt WR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020; 382(21): 1994–2004.
  545. Cutlip DE, Pinto DS. Extracranial carotid disease revascularization. Circulation. 2012; 126(22): 2636–2644.
  546. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(6): 572–586.
  547. Section 3: prevention and treatment of AKI. Kidney Int Suppl (2011). 2012; 2(1): 37–68.
  548. Romagnoli S, Ricci Z, Ronco C. Perioperative acute kidney injury: prevention, early recognition, and supportive measures. Nephron. 2018; 140(2): 105–110.
  549. Kheterpal S, Tremper KK, Heung M, et al. Development and validation of an acute kidney injury risk index for patients undergoing general surgery: results from a national data set. Anesthesiology. 2009; 110(3): 505–515.
  550. Rebholz CM, Inker LA, Chen Y, et al. Risk of ESRD and mortality associated with change in filtration markers. Am J Kidney Dis. 2017; 70(4): 551–560.
  551. McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016; 68(13): 1465–1473.
  552. Section 2: AKI definition. Kidney Int Suppl. 2012; 2(1): 19–36.
  553. Goren O, Matot I, et al. Perioperative acute kidney injury. Br J Anaesth. 2015; 115(Suppl 2): ii3–ii14.
  554. Zealley I, Wang H, Donnan PT, et al. Exposure to contrast media in the perioperative period confers no additional risk of acute kidney injury in surgical patients. Nephrol Dial Transplant. 2018; 33(10): 1751–1756.
  555. STARSurg Collaborative. Perioperative intravenous contrast administration and the incidence of acute kidney injury after major gastrointestinal surgery: prospective, multicentre cohort study. Br J Surg. 2020; 107: 1023–1032.
  556. Meersch M, Schmidt C, Zarbock A. Patient with chronic renal failure undergoing surgery. Curr Opin Anaesthesiol. 2016; 29(3): 413–420.
  557. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017; 390(10113): 2627–2642.
  558. Lavie CJ, Arena R, Alpert MA, et al. Management of cardiovascular diseases in patients with obesity. Nat Rev Cardiol. 2018; 15(1): 45–56.
  559. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016; 118(11): 1752–1770.
  560. De Hert S, Staender S, Fritsch G, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: Updated guideline from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2018; 35(6): 407–465.
  561. Lavie CJ, De Schutter A, Parto P, et al. Obesity and prevalence of cardiovascular diseases and prognosis — the obesity paradox updated. Prog Cardiovasc Dis. 2016; 58(5): 537–547.
  562. Elagizi A, Kachur S, Lavie CJ, et al. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2018; 61(2): 142–150.
  563. Valentijn TM, Galal W, Tjeertes EKM, et al. The obesity paradox in the surgical population. Surgeon. 2013; 11(3): 169–176.
  564. Hidvegi R, Puelacher C, Gualandro DM, et al. BASEL-P.M.I. Investigators. Obesity paradox and perioperative myocardial infarction/injury in non-cardiac surgery. Clin Res Cardiol. 2020; 109(9): 1140–1147.
  565. Ross R, Blair S, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. Circulation. 2016; 134(24): e653–e699.
  566. McAuley PA, Artero EG, Sui X, et al. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc. 2012; 87(5): 443–451.
  567. Pedersen BK. Body mass index-independent effect of fitness and physical activity for all-cause mortality. Scand J Med Sci Sports. 2007; 17(3): 196–204.
  568. Roman M, Monaghan A, Serraino GF, et al. Meta-analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes. Br J Surg. 2019; 106(3): 181–189.
  569. McCullough PA, Gallagher MJ, Dejong AT, et al. Cardiorespiratory fitness and short-term complications after bariatric surgery. Chest. 2006; 130(2): 517–525.
  570. Smith TB, Stonell C, Purkayastha S, et al. Cardiopulmonary exercise testing as a risk assessment method in non cardio-pulmonary surgery: a systematic review. Anaesthesia. 2009; 64(8): 883–893.
  571. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375(9733): 2215–2222.
  572. Kadoi Y. Anesthetic considerations in diabetic patients. Part II: intraoperative and postoperative management of patients with diabetes mellitus. J Anesth. 2010; 24(5): 748–756.
  573. Grant PJ, Cosentino F, Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
  574. American Diabetes Association. 15. Diabetes care in the hospital: standards of medical care in diabetes 2020. Diabetes Care. 2021; 44(Suppl 1): S211–S220.
  575. Shah NJ, Leis A, Kheterpal S, et al. Association of intraoperative hyperglycemia and postoperative outcomes in patients undergoing non-cardiac surgery: a multicenter retrospective study. BMC Anesthesiol. 2020; 20(1): 106.
  576. Aharaz A, Pottegård A, Henriksen DP, et al. Risk of lactic acidosis in type 2 diabetes patients using metformin: A case control study. PLoS One. 2018; 13(5): e0196122.
  577. Vogt AP, Bally L. Perioperative glucose management: Current status and future directions. Best Pract Res Clin Anaesthesiol. 2020; 34(2): 213–224.
  578. Pasquel FJ, Gomez-Huelgas R, Anzola I, et al. Predictive value of admission hemoglobin a1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care. 2015; 38(12): e202–e203.
  579. Carpenter DL, Gregg SR, Xu K, et al. Prevalence and impact of unknown diabetes in the ICU. Crit Care Med. 2015; 43(12): e541–e550.
  580. van den Boom W, Schroeder RA, Manning MW, et al. Effect of A1C and glucose on postoperative mortality in noncardiac and cardiac surgeries. Diabetes Care. 2018; 41(4): 782–788.
  581. Dhatariya K, Levy N, Kilvert A, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabet Med. 2012; 29(4): 420–433.
  582. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002; 346(13): 975–980.
  583. Kirschner M, do Ó Hartmann N, Parmentier S, et al. Primary thromboprophylaxis in patients with malignancies: daily practice recommendations by the hemostasis working party of the german society of hematology and medical oncology (DGHO), the society of thrombosis and hemostasis research (GTH), and the austrian society of hematology and oncology (ÖGHO). Cancers (Basel). 2021; 13(12): 2905.
  584. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022.
  585. COVIDSurg Collaborative, GlobalSurg Collaborative. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia. 2021; 76(6): 748–758.
  586. COVIDSurg Collaborative, GlobalSurg Collaborative. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study. Anaesthesia. 2022; 77(1): 28–39.
  587. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; 116(10): 1666–1687.
  588. Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(11): 1265–1273.
  589. Rohatgi N, Smilowitz NR, Reejhsinghani R. Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of COVID-19. JAMA Surg. 2022; 157(3): 187–188.
  590. Deng JZ, Chan JS, Potter AL, et al. The risk of postoperative complications after major elective surgery in active or resolved COVID-19 in the united states. Ann Surg. 2022; 275(2): 242–246.
  591. Anesthesia Patient Safety Foundation. American Society of Anesthesiologists and Anesthesia Patient Safety Foundation Joint Statement on Elective Surgery and Anesthesia for Patients after COVID-19 Infection. https://www.apsf.org/newsupdates/asa-and-apsf-joint-statement-on-elective-surgery-and-anesthesia-forpatients-after-covid-19-infection/ (March 30, 2022).
  592. Mellin-Olsen J, Staender S, Whitaker DK, et al. The Helsinki Declaration on patient safety in anaesthesiology. Eur J Anaesthesiol. 2010; 27(7): 592–597.
  593. De Hert S. Perioperative monitoring: anaesthesiology. In: Camm AJ, Lüscher TF, Maurer G, Serruys PW. ed. ESC CardioMed. 3rd ed. Oxford University Press, Oxford 2018: 2683–2686.
  594. Hamilton-Davies C, Mythen MG, Salmon JB, et al. Comparison of commonly used clinical indicators of hypovolaemia with gastrointestinal tonometry. Intensive Care Med. 1997; 23(3): 276–281.
  595. Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med. 2013; 41(7): 1774–1781.
  596. Gaba DM. Improving anesthesiologists' performance by simulating reality. Anesthesiology. 1992; 76(4): 491–494.
  597. Runciman WB. Commentary on equipment recommendations. Eur J Anaesthesiol Suppl. 1993; 7: 16–18.
  598. Block FE, Nuutinen L, Ballast B. Optimization of alarms: a study on alarm limits, alarm sounds, and false alarms, intended to reduce annoyance. J Clin Monit Comput. 1999; 15: 75–83.
  599. De Hert S, Moerman A. Anesthetic preconditioning: have we found the holy grail of perioperative cardioprotection? J Cardiothorac Vasc Anesth. 2018; 32(3): 1135–1136.
  600. Bijker JB, van Klei WA, Kappen TH, et al. Incidence of intraoperative hypotension as a function of the chosen definition: literature definitions applied to a retrospective cohort using automated data collection. Anesthesiology. 2007; 107(2): 213–220.
  601. Vernooij LM, van Klei WA, Machina M, et al. Different methods of modelling intraoperative hypotension and their association with postoperative complications in patients undergoing non-cardiac surgery. Br J Anaesth. 2018; 120(5): 1080–1089.
  602. Sessler DI, Bloomstone JA, Aronson S, et al. Perioperative Quality Initiative consensus statement on intraoperative blood pressure, risk and outcomes for elective surgery. Br J Anaesth. 2019; 122(5): 563–574.
  603. Sessler DI, Meyhoff CS, Zimmerman NM, et al. Period-dependent associations between hypotension during and for four days after noncardiac surgery and a composite of myocardial infarction and death: a substudy of the POISE-2 trial. Anesthesiology. 2018; 128(2): 317–327.
  604. Ladha KS, Beattie WS, Tait G, et al. Association between preoperative ambulatory heart rate and postoperative myocardial injury: a retrospective cohort study. Br J Anaesth. 2018; 121(4): 722–729.
  605. Abbott TEF, Ackland GL, Archbold RA, et al. Preoperative heart rate and myocardial injury after non-cardiac surgery: results of a predefined secondary analysis of the VISION study. Br J Anaesth. 2016; 117(2): 172–181.
  606. Abbott TEF, Minto G, Lee AM, et al. Elevated preoperative heart rate is associated with cardiopulmonary and autonomic impairment in high-risk surgical patients. Br J Anaesth. 2017; 119(1): 87–94.
  607. Ruetzler K, Yilmaz HO, Turan A, et al. Intra-operative tachycardia is not associated with a composite of myocardial injury and mortality after noncardiac surgery: A retrospective cohort analysis. Eur J Anaesthesiol. 2019; 36(2): 105–113.
  608. Straarup TS, Hausenloy DJ, Rolighed Larsen JK. Cardiac troponins and volatile anaesthetics in coronary artery bypass graft surgery: A systematic review, meta-analysis and trial sequential analysis. Eur J Anaesthesiol. 2016; 33(6): 396–407.
  609. Landoni G, Lomivorotov VV, Nigro Neto C, et al. Volatile anesthetics versus total intravenous anesthesia for cardiac surgery. N Engl J Med. 2019; 380(13): 1214–1225.
  610. Lurati Buse GAL, Schumacher P, Seeberger E, et al. Randomized comparison of sevoflurane versus propofol to reduce perioperative myocardial ischemia in patients undergoing noncardiac surgery. Circulation. 2012; 126(23): 2696–2704.
  611. Rodgers A, Walker N, Schug S, et al. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ. 2000; 321(7275): 1493.
  612. Bos EME, Hollmann M, Lirk P. Safety and efficacy of epidural analgesia. Curr Opin Anaesthesiol. 2017; 30(6): 736–742.
  613. Gogarten W, Vandermeulen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol. 2010; 27(12): 999–1015.
  614. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg. 2011; 112(6): 1392–1402.
  615. Grocott MPW, Dushianthan A, Hamilton MA, et al. Optimisation Systematic Review Steering Group. Perioperative increase in global blood flow to explicit defined goals and outcomes following surgery. Cochrane Database Syst Rev. 2012; 11: CD004082.
  616. Cecconi M, Corredor C, Arulkumaran N, et al. Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups. Crit Care. 2013; 17(2): 209.
  617. Arulkumaran N, Corredor C, Hamilton MA, et al. Cardiac complications associated with goal-directed therapy in high-risk surgical patients: a meta-analysis. Br J Anaesth. 2014; 112(4): 648–659.
  618. Nicklas JY, Diener O, Leistenschneider M, et al. Personalised haemodynamic management targeting baseline cardiac index in high-risk patients undergoing major abdominal surgery: a randomised single-centre clinical trial. Br J Anaesth. 2020; 125(2): 122–132.
  619. Taenzer AH, Pyke JB, McGrath SP. A review of current and emerging approaches to address failure-to-rescue. Anesthesiology. 2011; 115(2): 421–431.
  620. Pyke J, Taenzer AH, Renaud CE, et al. Developing a continuous monitoring infrastructure for detection of inpatient deterioration. Jt Comm J Qual Patient Saf. 2012; 38(9): 428–431.
  621. McGrath SP, Taenzer AH, Karon N, et al. Surveillance monitoring management for general care units: strategy, design, and implementation. Jt Comm J Qual Patient Saf. 2016; 42(7): 293–302.
  622. Taenzer AH, Spence BC. The afferent limb of rapid response systems: continuous monitoring on general care units. Crit Care Clin. 2018; 34(2): 189–198.
  623. Liu SS, Wu CL. The effect of analgesic technique on postoperative patient-reported outcomes including analgesia: a systematic review. Anesth Analg. 2007; 105(3): 789–808.
  624. White PF, Kehlet H. Postoperative pain management and patient outcome: time to return to work! Anesth Analg. 2007; 104(3): 487–489.
  625. Turan A, Leung S, Bajracharya GR, et al. Acute postoperative pain is associated with myocardial injury after noncardiac surgery. Anesth Analg. 2020; 131(3): 822–829.
  626. Olsen AM, Fosbøl E, Lindhardsen J, et al. Long-Term cardiovascular risk of nonsteroidal anti-inflammatory drug use according to time passed after first-time myocardial infarction. Circulation. 2012; 126(16): 1955–1963.
  627. Schmidt M, Sørensen HT, Pedersen L. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. BMJ. 2018; 362: k3426.
  628. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009; 103(9): 1227–1237.
  629. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009; 2(3): 155–163.
  630. Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007; 115: 1634–1642.
  631. Schug SA, Joshi GP, Camu F, et al. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data. Anesth Analg. 2009; 108(1): 299–307.
  632. Liu SS, Bae JJ, Bieltz M, et al. Association of perioperative use of nonsteroidal anti-inflammatory drugs with postoperative myocardial infarction after total joint replacement. Reg Anesth Pain Med. 2012; 37(1): 45–50.
  633. Schmidt M, Lamberts M, Olsen AMS, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016; 37(13): 1015–1023.
  634. Khanna AK, Shaw AD, Stapelfeldt WH, et al. Intraoperative hypotension is associated with adverse clinical outcomes after noncardiac surgery. Anesth Analg. 2021; 132(6): 1654–1665.
  635. Aldington S, Shirtcliffe P, Weatherall M, et al. Increased risk of cardiovascular events with parecoxib/valdecoxib: a systematic review and meta-analysis. N Z Med J. 2005; 118(1226): U1755.
  636. Devereaux PJ, Sessler DI. Cardiac complications in patients undergoing major noncardiac surgery. N Engl J Med. 2015; 373(23): 2258–2269.
  637. Sabate S, Mases A, Guilera N, et al. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in noncardiac surgery. Br J Anaesth. 2011; 107(6): 879–890.
  638. Smilowitz NR, Redel-Traub G, Hausvater A, et al. Myocardial injury after noncardiac surgery: a systematic review and meta-analysis. Cardiol Rev. 2019; 27(6): 267–273.
  639. Smilowitz NR, Gupta N, Guo Yu, et al. Perioperative acute myocardial infarction associated with non-cardiac surgery. Eur Heart J. 2017; 38(31): 2409–2417.
  640. Master AM, Dack S, Jaffe HL. Postoperative coronary artery occlusion. JAMA. ; 1938: 1415–1418.
  641. Devereaux PJ, Xavier D, Pogue J, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med. 2011; 154(8): 523–528.
  642. Borges FK, Devereaux PJ. Physicians should obtain perioperative cardiac troponin measurements in at-risk patients undergoing noncardiac surgery. Clin Chem. 2021; 67(1): 50–53.
  643. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Circulation. 2018; 138: e618–e651.
  644. Toda H, Nakamura K, Shimizu K, et al. Effects of bisoprolol transdermal patches for prevention of perioperative myocardial injury in high-risk patients undergoing non-cardiac surgery — multicenter randomized controlled study. Circ J. 2020; 84(4): 642–649.
  645. Devereaux PJ, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. Eur Heart J. 2020; 41(32): 3083–3091.
  646. Ruetzler K, Smilowitz NR, Berger JS, et al. Diagnosis and management of patients with myocardial injury after noncardiac surgery: a scientific statement from the American Heart Association. Circulation. 2021; 144(19): e287–e305.
  647. Borges FK, Sheth T, Patel A, et al. Accuracy of physicians in differentiating type 1 and type 2 myocardial infarction based on clinical information. CJC Open. 2020; 2(6): 577–584.
  648. Gualandro DM, Puelacher C, Lurati Buse G, et al. Incidence and outcomes of perioperative myocardial infarction/injury diagnosed by high-sensitivity cardiac troponin I. Clin Res Cardiol. 2021; 110(9): 1450–1463.
  649. Park J, Oh AhR, Kwon JH, et al. Association between cardiologist evaluation and mortality in myocardial injury after non-cardiac surgery. Heart. 2022; 108(9): 695–702.
  650. Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018; 391(10137): 2325–2334.
  651. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37(27): 2129–2200.
  652. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Respir J. 2019; 54(3): 543–603.
  653. Marti C, John G, Konstantinides S, et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J. 2015; 36(10): 605–614.
  654. Neely RC, Byrne JG, Gosev I, et al. Surgical embolectomy for acute massive and submassive pulmonary embolism in a series of 115 patients. Ann Thorac Surg. 2015; 100(4): 1245–1251.
  655. Conen D, Alonso-Coello P, Douketis J, et al. Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery. Eur Heart J. 2020; 41(5): 645–651.
  656. AlTurki A, Marafi M, Proietti R, et al. Major adverse cardiovascular events associated with postoperative atrial fibrillation after noncardiac surgery: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol. 2020; 13(1): e007437.
  657. Chebbout R, Heywood EG, Drake TM, et al. A systematic review of the incidence of and risk factors for postoperative atrial fibrillation following general surgery. Anaesthesia. 2018; 73(4): 490–498.
  658. Albini A, Malavasi VL, Vitolo M, et al. Long-term outcomes of postoperative atrial fibrillation following non cardiac surgery: A systematic review and metanalysis. Eur J Intern Med. 2021; 85: 27–33.
  659. Hyun J, Cho MS, Nam GB, et al. Natural course of new-onset postoperative atrial fibrillation after noncardiac surgery. J Am Heart Assoc. 2021; 10(7): e018548.
  660. Heywood EG, Drake TM, Bradburn M, et al. Atrial fibrillation after gastrointestinal surgery: incidence and associated risk factors. J Surg Res. 2019; 238: 23–28.
  661. Lin MH, Kamel H, Singer DE, et al. Perioperative/Postoperative atrial fibrillation and risk of subsequent stroke and/or mortality. Stroke. 2019; 50(6): 1364–1371.
  662. Dobrev D, Aguilar M, Heijman J, et al. Postoperative atrial fibrillation: mechanisms, manifestations and management. Nat Rev Cardiol. 2019; 16(7): 417–436.
  663. Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA. 2004; 291(14): 1720–1729.
  664. Villareal RP, Hariharan R, Liu BC, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol. 2004; 43(5): 742–748.
  665. Cardinale D, Sandri MT, Colombo A, et al. Prevention of atrial fibrillation in high-risk patients undergoing lung cancer surgery: the PRESAGE trial. Ann Surg. 2016; 264(2): 244–251.
  666. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013; 2013(1): CD003611.
  667. Ozaydin M, Icli A, Yucel H, et al. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. Eur Heart J. 2013; 34(8): 597–604.
  668. O'Neal JB, Billings FT, Liu X, et al. Effect of preoperative beta-blocker use on outcomes following cardiac surgery. Am J Cardiol. 2017; 120(8): 1293–1297.
  669. Buckley MS, Nolan PE, Slack MK, et al. Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. Pharmacotherapy. 2007; 27(3): 360–368.
  670. Riber LP, Christensen TD, Jensen HK, et al. Amiodarone significantly decreases atrial fibrillation in patients undergoing surgery for lung cancer. Ann Thorac Surg. 2012; 94(2): 339–346.
  671. Tisdale JE, Wroblewski HA, Wall DS, et al. A randomized trial evaluating amiodarone for prevention of atrial fibrillation after pulmonary resection. Ann Thorac Surg. 2009; 88(3): 886–895.
  672. Yuan X, Du J, Liu Qi, et al. Defining the role of perioperative statin treatment in patients after cardiac surgery: A meta-analysis and systematic review of 20 randomized controlled trials. Int J Cardiol. 2017; 228: 958–966.
  673. Zheng Z, Jayaram R, Jiang L, et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med. 2016; 374(18): 1744–1753.
  674. Fairley JL, Zhang L, Glassford NJ, et al. Magnesium status and magnesium therapy in cardiac surgery: A systematic review and meta-analysis focusing on arrhythmia prevention. J Crit Care. 2017; 42: 69–77.
  675. Tabbalat RA, Hamad NM, Alhaddad IA, et al. Effect of colchiciNe on the inciDence of atrial fibrillation in open heart surgery patients: END-AF trial. Am Heart J. 2016; 178: 102–107.
  676. Wang W, Mei Y, Yuan X, et al. Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation. J Thorac Cardiovasc Surg. 2016; 151(1): 80–85.
  677. Dieleman JM, Nierich AP, Rosseel PM, et al. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA. 2012; 308(17): 1761–1767.
  678. Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. Lancet. 2015; 386(10000): 1243–1253.
  679. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009; 2(6): 652–659.
  680. Gillinov AM, Bagiella E, Moskowitz AJ, et al. CTSN. Rate control versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med. 2016; 374(20): 1911–1921.
  681. Saxena A, Dinh DT, Smith JA, et al. Usefulness of postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J Cardiol. 2012; 109(2): 219–225.
  682. Gialdini G, Nearing K, Bhave PD, et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA. 2014; 312(6): 616–622.
  683. Horwich P, Buth KJ, Légaré JF. New onset postoperative atrial fibrillation is associated with a long-term risk for stroke and death following cardiac surgery. J Card Surg. 2013; 28(1): 8–13.
  684. Ahlsson A, Fengsrud E, Bodin L, et al. Postoperative atrial fibrillation in patients undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a doubled cardiovascular mortality. Eur J Cardiothorac Surg. 2010; 37(6): 1353–1359.
  685. Butt JH, Xian Y, Peterson ED, et al. Long-term thromboembolic risk in patients with postoperative atrial fibrillation after coronary artery bypass graft surgery and patients with nonvalvular atrial fibrillation. JAMA Cardiol. 2018; 3(5): 417–424.
  686. Butt JH, Olesen JB, Havers-Borgersen E, et al. Risk of thromboembolism associated with atrial fibrillation following noncardiac surgery. J Am Coll Cardiol. 2018; 72(17): 2027–2036.
  687. Selim M. Perioperative stroke. N Engl J Med. 2007; 356(7): 706–713.
  688. Macellari F, Paciaroni M, Agnelli G, et al. Perioperative stroke risk in nonvascular surgery. Cerebrovasc Dis. 2012; 34(3): 175–181.
  689. Mashour GA, Shanks AM, Kheterpal S. Perioperative stroke and associated mortality after noncardiac, nonneurologic surgery. Anesthesiology. 2011; 114: 1289–1296.
  690. Ng JLW, Chan MTV, Gelb AW. Perioperative stroke in noncardiac, nonneurosurgical surgery. Anesthesiology. 2011; 115(4): 879–890.
  691. Walicka M, Tuszyńska A, Chlebus M, et al. Predictors of in-hospital mortality in surgical wards: a multivariable retrospective cohort analysis of 2,800,069 hospitalizations. World J Surg. 2021; 45(2): 480–487.
  692. Mattingly AS, Lerman BJ, Popat R, et al. Association of sex with postoperative mortality among patients with heart failure who underwent elective noncardiac operations. JAMA Netw Open. 2019; 2(11): e1914420.
  693. World Health Organization. Prevalence of anaemia in women of reproductive age (aged 15–49) (%). In: Global Health Observatory. Geneva: World Health Organization; 2022. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalenceof-anaemia-in-women-of-reproductive-age-(-).
  694. Gombotz H, Schreier G, Neubauer S, et al. Gender disparities in red blood cell transfusion in elective surgery: a post hoc multicentre cohort study. BMJ Open. 2016; 6(12): e012210.
  695. Riesenhuber M, Spannbauer A, Rauscha F, et al. Sex differences and long-term outcome in patients with pacemakers. Front Cardiovasc Med. 2020; 7: 569060.
  696. Varma N, Mittal S, Prillinger JB, et al. Survival in women versus men following implantation of pacemakers, defibrillators, and cardiac resynchronization therapy devices in a large, nationwide cohort. J Am Heart Assoc. 2017; 6(5).
  697. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005; 112(12): 1687–1691.
  698. Aktaa S, Batra G, Wallentin L, et al. European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes. 2022; 8(1): 4–13.
  699. Minchin M, Roland M, Richardson J, et al. Quality of care in the United Kingdom after removal of financial incentives. N Engl J Med. 2018; 379(10): 948–957.
  700. Song Z, Ji Y, Safran DG, et al. Health care spending, utilization, and quality 8 years into global payment. N Engl J Med. 2019; 381(3): 252–263.
  701. Arbelo E, Aktaa S, Bollmann A, et al. Quality indicators for the care and outcomes of adults with atrial fibrillation. Europace. 2021; 23(4): 494–495.
  702. Schiele F, Aktaa S, Rossello X, et al. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc Care. 2021; 10(2): 224–233.
  703. Aktaa S, Abdin A, Arbelo E, et al. European Society of Cardiology Quality Indicators for the care and outcomes of cardiac pacing: developed by the Working Group for Cardiac Pacing Quality Indicators in collaboration with the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2022; 24(1): 165–172.
  704. Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021; 42(23): 2298.
  705. Batra G, Aktaa S, Wallentin L, et al. Methodology for the development of international clinical data standards for common cardiovascular conditions: European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart). Eur Heart J Qual Care Clin Outcomes. 2021 [Epub ahead of print].



Polish Heart Journal (Kardiologia Polska)